

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/077060 A2

(51) International Patent Classification⁷: **G01N 33/574**

(21) International Application Number:
PCT/CA2004/000280

(22) International Filing Date: 26 February 2004 (26.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/451,382 27 February 2003 (27.02.2003) US

(71) Applicant (for all designated States except US): **MOUNT SINAI HOSPITAL** [CA/CA]; 600 University Avenue, Room 970, Toronto, Ontario M5G 1X5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DIAMANDIS, Eleftherios, P.** [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA). **PETRAKI, Constantina, D.** [GR/GR]; Department of Pathology, Evangelismos Hospital, Phedriadon 109, GR-113 64 Athens (GR).

(74) Agent: **KURDYDYK, Linda**; McCarthy Tetrault, 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower, Toronto Dominion Centre, Toronto, Ontario M5K 1E6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR DETECTION OF RENAL CELL CARCINOMA

(57) Abstract: Methods for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.



WO 2004/077060 A2

TITLE: Assay for Detection of Renal Cell Carcinoma**FIELD OF THE INVENTION**

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating renal cell carcinoma.

5 BACKGROUND OF THE INVENTION

Kallikreins are a subgroup of secreted serine proteases, encoded by highly conserved and tightly clustered multigene families in humans, rats and mice. The human kallikrein gene family resides on chromosome 19q13.4 and is comprised of 15 members, whose genes are designated as *KLK1* to *KLK15* and the corresponding proteins as hK1 to hK15 (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204; 10 Yousef GM, Chang A, Scorilas A, et al., *Biochem Biophys Res Commun*. 2000;276:125-133; Diamandis EP, Yousef GM, Clements J, et al. *Clin Chem* .2000;46:1855-1858). Kallikreins are expressed in a wide variety of tissues and are found in many biological fluids (e.g. cerebrospinal fluid, serum, seminal plasma, milk, etc.) where they are predicted to process specific substrates. Kallikreins may participate in cascade reactions similar to those involved in digestion, fibrinolysis, coagulation, wound healing and apoptosis (Yousef GM, 15 Diamandis EP., *Endocr Rev* .2001;22:184-204). Many kallikreins have been found to be differentially expressed in endocrine-related malignancies (Diamandis EP, Yousef GM, *Expert Rev. Mol. Diagn* .2001;1:182-190), including prostate (Barry MJ. Clinical practice, *N Engl J Med* .2001;344:1373-1377; Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al., *Crit Rev Clin Lab Sci* .1998;35:275-368; and Yousef GM, Scorilas A, Jung K, et al., *J Biol Chem* .2001;276:53-61), ovarian(Kim H, Scorilas A, Katsaros D, et al., *Br J Cancer*, 2001;84:643-650; Anisowicz A, Sotiropoulou G, Stenman, et al., *Mol Med* .1996;2:624- 20 636; Tanimoto H, Underwood LJ, Shigemasa K, et al., *Cancer* .1999;86:2074-2082; Magklara A, Scorilas A, Katsaros D, et al., *Clin Cancer Res* .2001;7:806-811; Yousef GM, Kyriakopoulou LG, Scorilas A, et al., *Cancer Res* .2001;61:7811-7818; Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118), breast (Yousef GM, Magklara A, Chang A, et al., *Cancer Res* .2001;61:3425- 25 3431; Yousef GM, Chang A, Diamandis EP; *J Biol Chem* .2000;275:11891-11898; and Yousef GM, Magklara A, Diamandis EP, *Genomics* .2000;69:331-341), and testicular cancer (Luo LY, Rajpert-De Meyts ER, Jung K, et al., 2001;85:220-224). In addition, many kallikrein genes examined thus far are under steroid hormone regulation, implicating a role for kallikreins in endocrine-related tissues (Yousef GM, Diamandis EP., *Endocr Rev.*, 2001;22:184-204). Furthermore, hK6, hK10 and hK11 have been recently identified as 30 novel serological ovarian cancer biomarkers (Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118 Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P., *Clin Biochem*. 2000;33:579-583, and Diamandis EP, Okui A, Mitsui S, et al., *Cancer Res* .2002;62:295-300).

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks inherent in the prior art and provide 35 sensitive and accurate methods for the detection of renal cell carcinoma. It has been found that one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and polynucleotides encoding the polypeptides, have particular application in the detection of renal cell carcinoma. Thus, the kallikrein markers constitute biomarkers for the diagnosis, monitoring, progression, treatment, and prognosis of renal cell carcinoma, and they may be used as biomarkers before

surgery or after relapse.

In accordance with the methods of the invention, the presence of levels of kallikrein markers in a sample can be assessed, for example by detecting the presence in the sample of (a) polypeptides or polypeptide fragments corresponding to the markers; (b) metabolites which are produced directly or indirectly by polypeptides corresponding to the markers; (c) transcribed nucleic acids or fragments thereof having at least a portion with which the markers are substantially identical; and/or (c) transcribed nucleic acids or fragments thereof, wherein the nucleic acids hybridize with the markers.

In an embodiment, the invention provides a method for detecting one or more kallikrein polypeptides wherein the kallikrein polypeptides are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma in a patient comprising:

- (a) obtaining a sample from a patient;
- (b) detecting or identifying in the sample one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (c) comparing the detected amounts with amounts detected for a standard.

The term "detect" or "detecting" includes assaying, assessing, imaging or otherwise establishing the presence or absence of the target kallikrein polypeptides or polynucleotides encoding the polypeptides, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of renal cell carcinoma, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications. The kallikrein markers can be detected individually, sequentially, or simultaneously.

According to a method involving one or more kallikrein polypeptides the levels in the sample of one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma, are compared with the normal levels of the kallikrein polypeptides, in samples of the same type obtained from controls (e.g. samples from individuals not afflicted with renal cell carcinoma). Significantly different levels in the sample of the kallikrein polypeptides relative to the normal levels in a control is indicative of renal cell carcinoma.

In an embodiment, the invention provides a method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. The kallikrein markers can be detected using antibodies that bind to the kallikrein markers or parts thereof.

Thus, the invention provides a method of assessing whether a patient is afflicted with or has a pre-disposition for renal cell carcinoma, the method comprising comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and

- 3 -

- 5 (b) normal levels of the kallikrein polypeptides, in samples of the same type obtained from control patients not afflicted with renal cell carcinoma, wherein significantly different levels of the kallikrein polypeptides, relative to the corresponding normal levels of the kallikrein polypeptides, is an indication that the patient is afflicted with renal cell carcinoma.

In an embodiment of a method of assessing whether a patient is afflicted with renal cell carcinoma (e.g. screening, detection of a recurrence, reflex testing), the method comprises comparing:

- 10 (a) levels of one or more, preferably 2 or more, kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides, in a control non-renal cell carcinoma sample.

A significant difference between the levels of the kallikrein polypeptides in the patient sample and the normal levels is an indication that the patient is afflicted with renal cell carcinoma. In an embodiment, the levels of kallikrein markers are significantly higher and are indicative of tumors of high grade, advanced stage disease, and/or lower survival.

15

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient. This method comprises comparing:

- (a) levels of one or more kallikrein polypeptides in a sample from the patient obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- 20 (b) levels of the kallikrein polypeptides in a second sample obtained from the patient following therapy.

A significant difference between the levels of the kallikrein polypeptides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell carcinoma.

25

The "therapy" may be any therapy for treating renal cell carcinoma including but not limited to chemotherapy, immunotherapy, gene therapy, radiation therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy, for example, to evaluate the reduction in tumor burden.

30 In an aspect, the invention provides a method for monitoring the progression of renal cell carcinoma in a patient, the method comprising:

- (a) detecting in a patient sample at a first time point, one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- 35 (b) repeating step (a) at a subsequent point in time; and
- (c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of renal cell carcinoma in the patient.

In another aspect, the invention provides a method for assessing the aggressiveness or indolence of renal cell carcinoma (e.g. staging), the method comprising comparing:

- 4 -

- (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels of the kallikrein polypeptides in a control sample.

5 A significant difference between the levels in the sample and the normal levels is an indication that the cancer is aggressive or indolent.

The invention provides a method for determining whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing:

- 10 (a) levels of one or more kallikrein polypeptides in a sample from the patient wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma; and
- (b) normal levels (or non-metastatic levels) of the kallikrein polypeptides in a control sample.

A significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

15 The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, and a method of selecting an agent for inhibiting renal cell carcinoma in a patient.

The invention further provides a method of inhibiting renal cell carcinoma in a patient comprising:

- 20 (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing levels of one or more kallikrein polypeptides, in each of the aliquots, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma;
- 25 (d) administering to the patient at least one of the test agents which alters the levels of the kallikrein polypeptides in the aliquot containing that test agent, relative to other test agents.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- 30 (b) comparing levels of kallikrein polypeptides in each of the aliquots, wherein the polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the kallikrein polypeptides in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

35 In embodiments of the methods of the invention, two, three, or four kallikrein polypeptides are employed. In preferred embodiments, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10; kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. In a particular embodiment, the kallikrein polypeptides are selected from the group consisting of kallikrein 6, kallikrein 10, and kallikrein 11.

Other methods of the invention employ one or more polynucleotides capable of hybridizing to polynucleotides encoding kallikrein polypeptides wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 associated with renal cell carcinoma. Methods for detecting polynucleotides encoding kallikrein polypeptides can be used to monitor renal cell carcinoma by detecting
5 the nucleic acids.

Thus, the present invention relates to a method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting polynucleotides encoding kallikrein polypeptides in the sample, wherein the kallikrein polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The presence of different
10 levels of polynucleotides encoding the kallikrein polypeptides, in the sample compared to a standard or control is indicative of disease, disease stage, and/or prognosis, e.g. progression-free and overall survival.

In an embodiment, the invention provides methods for determining the presence or absence of renal cell carcinoma in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides wherein the kallikrein
15 polypeptides comprise kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject. Within certain embodiments, mRNA is detected via polymerase chain reaction using, for example oligonucleotide primers that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids.
20 Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to polynucleotides encoding kallikrein polypeptides, or complements of such nucleic acids.

When using mRNA detection, the method may be carried out by combining isolated mRNA with reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification
25 reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of polynucleotides encoding kallikrein polypeptides in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of polynucleotides encoding kallikrein polypeptides. The analysis step may be further
30 accomplished by quantitatively detecting the presence of polynucleotides encoding kallikrein polypeptides in the amplification product, and comparing the quantity of markers detected against a panel of expected values for the known presence or absence of the markers in normal and malignant tissue derived using similar primers.

In embodiments of the invention, one, two, three or four polynucleotides encoding kallikrein
35 polypeptides are employed. In preferred embodiments, the polynucleotides encode kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and kallikrein 6, kallikrein 10 and kallikrein 11.

The invention also provides a diagnostic composition comprising kallikrein polypeptides, or polynucleotides encoding the polypeptides, or agents that bind to the polypeptides or nucleic acids.

In an embodiment, the composition comprises probes that specifically hybridize to polynucleotides

- 6 -

encoding kallikrein polypeptides, or fragments thereof. In another embodiment a composition is provided comprising specific primer pairs capable of amplifying polynucleotides encoding kallikrein polypeptides, using polymerase chain reaction methodologies. In a still further embodiment, the composition comprises agents that bind to kallikrein polypeptides (e.g. antibodies) or fragments thereof. Probes, primers, and agents
5 can be labeled with detectable substances.

In an aspect the invention provides an *in vivo* method comprising administering to a subject agents that have been constructed to target kallikrein polypeptides.

The invention therefore contemplates an *in vivo* method comprising administering to a mammal imaging agents that carry labels for imaging and that bind to kallikrein polypeptides, and then imaging the
10 mammal.

Still further the invention relates to therapeutic applications for renal cell carcinoma employing kallikrein polypeptides and polynucleotides encoding the polypeptides, and/or agents identified using methods of the invention.

The invention also includes kits for carrying out methods of the invention. In an embodiment, the
15 kit is for assessing whether a patient is afflicted with renal cell carcinoma and it comprises reagents for assessing one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

In another aspect the invention relates to a kit for assessing the suitability of each of a plurality of test compounds for inhibiting renal cell carcinoma in a patient. The kit comprises reagents for assessing
20 kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The kit may also comprise a plurality of test agents or compounds.

The invention contemplates a kit for assessing the presence of renal cell carcinoma cells, wherein the kit comprises antibodies specific for selected markers, wherein the markers comprise or are selected from
25 the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

Additionally the invention provides a kit for assessing the renal cell carcinoma carcinogenic potential of a test compound. The kit comprises renal cell carcinoma cells and reagents for assessing kallikrein markers, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

30 In an aspect the invention provides a method of treating a patient afflicted with renal cell carcinoma comprising providing to cells of a patient antisense oligonucleotides complementary to polynucleotides encoding one or more kallikrein polypeptides, which are overexpressed in renal cell carcinoma. In an alternative method, expression of genes corresponding to one or more kallikrein polypeptides which are underexpressed in renal cell carcinoma are increased.

35 The invention relates to a method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma comprising inhibiting or increasing expression (or overexpression) of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, that are either overexpressed or underexpressed, in renal cell carcinoma.

- 7 -

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered correlations between expression of certain markers and renal cell carcinoma. The combinations of markers described herein may provide sensitive methods for detecting renal cell carcinoma. The levels of expression of a combination of markers described herein may correlate with the presence of renal cell carcinoma or a pre-malignant condition in a patient. Methods are provided for detecting the presence of renal cell carcinoma in a sample, the absence of renal cell carcinoma in a sample, the stage of a renal cell carcinoma, the grade of a renal cell carcinoma, the benign or malignant nature of a renal cell carcinoma, the metastatic potential of a renal cell carcinoma, assessing the histological type of neoplasm associated with the renal cell carcinoma, the indolence or aggressiveness of the cancer, and other characteristics of renal cell carcinoma that are relevant to prevention, diagnosis, characterization, and therapy of renal cell carcinoma in a patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting renal cell carcinoma, assessing the efficacy of a therapy for renal cell carcinoma, monitoring the progression of renal cell carcinoma, selecting an agent or therapy for inhibiting renal cell carcinoma, treating a patient afflicted with renal cell carcinoma, inhibiting renal cell carcinoma in a patient, and assessing the carcinogenic potential of a test compound.

Glossary

The terms "sample", "biological sample", and the like, mean a material known or suspected of expressing or containing kallikrein polypeptides associated with renal cell carcinoma, or polynucleotides encoding the polypeptides. The test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like. Nucleic acids and polypeptides may be isolated from the samples and utilized in the methods of the invention. In a preferred embodiment, the sample is a serum sample.

The term "subject" or "patient" refers to a warm-blooded animal such as a mammal, which is suspected of having renal cell carcinoma or a condition, disease, or syndrome associated with renal cell carcinoma. Preferably, "subject" refers to a human.

"Kallikrein polypeptides" or "kallikrein markers" include one or more of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11. The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The amino acid sequences for native kallikrein polypeptides employed in the

- 8 -

present invention include the sequences found in GenBank for each polypeptide as shown in Table 1, and in SEQ ID NO: 1 (kallikrein 5), NO. 4 (kallikrein 6), NO. 8 (kallikrein 10), and NOs. 11 and 12 (kallikrein 11), or a portion thereof. Other useful polypeptides are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity), and preferably retain the immunogenic activity of the corresponding native-sequence kallikrein polypeptide.

A "native-sequence polypeptide" comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

The term "native-sequence polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants.

The term "polypeptide variant" means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in the GenBank Accession Nos. in Table 1 and shown in SEQ ID NOS 1, 4, 8, 11, and 12. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOS: 1, 4, 8, 11, and 12, including variants from other species, but excludes a native-sequence polypeptide.

An allelic variant may also be created by introducing substitutions, additions, or deletions into a nucleic acid encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a kallikrein polypeptide homolog, for example, the murine kallikrein polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a kallikrein polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., *Nucleic Acids Research* 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. *J. Molec. Biol.* 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. *J. Mol. Biol.* 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

Kallikrien polypeptides include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a kallikrein polypeptide operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same kallikrein polypeptide). Within the fusion protein, the term "operably linked" is intended to indicate that the kallikrein polypeptide and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the kallikrein polypeptide. A useful fusion protein is a GST fusion protein in which a kallikrein polypeptide is fused to the C-terminus of GST sequences. Another example of a fusion protein is an immunoglobulin fusion protein in which all or part of a kallikrein polypeptide is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

Kallikrein polypeptides may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

"Kallikrein polynucleotides" or "polynucleotides encoding kallikrein polypeptides" refers to one or more of kallikrein 5 polynucleotide (KLK5), kallikrein 6 polynucleotide (KLK6), kallikrein 10 polynucleotide (KLK10), and kallikrein 11 polynucleotide (KLK11). The term includes polynucleotides that encode a native-sequence polypeptide, a polypeptide variant including a portion of a kallikrein polypeptide, an isoform, precursor, and chimeric polypeptide.

The polynucleotide sequences encoding native kallikrein polypeptides employed in the present invention include the nucleic acid sequences of the GenBank Accession Nos. identified in Table 1, and in SEQ ID NOs: 2 and 3 (KLK5), NOs. 5, 6, and 7 (KLK6), NOs. 9 and 10 (KLK10), and NOs. 13 and 14 (KLK11), or a fragment thereof.

Polynucleotides encoding kallikrein polypeptides include nucleic acid sequences complementary to these nucleic acids, and polynucleotides that are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity).

5 Kallikrein polynucleotides also include sequences which differ from a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14, due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a kallikrein polypeptide may result in silent mutations that do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to
10 natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a kallikrein polypeptide.

Kallikrein polynucleotides also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 3, 5, 6, 7, 9, 10, 13, and 14. Appropriate stringency conditions which
15 promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In
20 addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

Kallikrein polynucleotides also include truncated nucleic acids or nucleic acid fragments and variant forms of the nucleic acids that arise by alternative splicing of an mRNA corresponding to a DNA.

Kallikrein polynucleotides are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-
25 coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method.

One or more kallikrein polypeptides or kallikrein polynucleotides are detected in the present invention. In an aspect, the kallikrein polypeptides comprise kallikrein 6; kallikrein 6 and kallikrein 10;
30 kallikrein 6 and kallikrein 11; kallikrein 6, kallikrein 10 and kallikrein 11; or kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11. In another aspect, the kallikrein polynucleotides comprise KLK6; KLK6 and KLK10; KLK6 and KLK11; KLK6, KLK10 and KLK11; or KLK5, KLK6, KLK10 and KLK11

General Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of renal cell
35 carcinoma involving kallikrein polypeptides, and polynucleotides encoding the polypeptides, and the identification of subjects with a predisposition to such disorders. Such methods may, for example, utilize polynucleotides encoding kallikrein polypeptides, and fragments thereof, and binding agents (e.g. antibodies aptamers) against kallikrein polypeptides, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of either over- or under-expression of kallikrein

polynucleotides, relative to a non-disorder state; and (2) the detection of either an over- or an under-abundance of kallikrein polypeptides, relative to a non-disorder state or the presence of modified (e.g., less than full length) kallikrein polypeptides that correlate with a disorder state, or a progression toward a disorder state.

5 The invention also contemplates a method for detecting renal cell carcinoma comprising producing a profile of levels of kallikrein polypeptides in cells from a patient, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and/or kallikrein 11, and comparing the profile with a reference to identify a protein profile for the test cells indicative of disease.

10 The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

15 The methods described herein can be adapted for diagnosing and monitoring renal cell carcinoma by detecting kallikrein polypeptides, or polynucleotides encoding the polypeptides in biological samples from a subject. These applications require that the amount of polypeptides or polynucleotides quantitated in a sample from a subject being tested be compared to a predetermined standard. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a control sample. Levels for control samples from healthy subjects or renal cell carcinoma subjects may be established by prospective and/or retrospective statistical studies. Healthy or normal subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of kallikrein polypeptides, or polynucleotides encoding same, compared to a control sample or previous levels quantitated for the same subject. A "significant difference" 20 in levels of markers or polynucleotides in a patient sample compared to a control or standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay, preferably the levels are at least about 1.5, 2, 3, 4, 5, or 6 times higher or lower, respectively, than the control or standard. The difference in levels of markers or polynucleotides may be a statistically significant difference.

25 In an embodiment, the levels of kallikrein markers, in particular kallikrein 6 and kallikrein 10, are significantly higher in subjects with renal cell carcinoma, more particularly renal cell carcinoma with tumors of high grade and/or advanced stage. In another embodiment, there is a statistically significant difference in kallikrein 6 levels and/or kallikrein 10 levels which are indicative of late stage disease and/or reduced disease survival.

30 **Nucleic Acid Methods/Assays**

35 As noted herein renal cell carcinoma may be detected based on the level of polynucleotides encoding kallikrein polypeptides in a sample. Techniques for detecting nucleic acid molecules such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of polynucleotides encoding kallikrein polypeptides, preferably they comprise 15 to 40 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P , ^3H , ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect polynucleotides encoding kallikrein polypeptides preferably in human cells. The nucleotide probes may also be useful in the diagnosis of renal cell carcinoma involving polynucleotides encoding kallikrein polypeptides, in monitoring the progression of such disorder; or monitoring a therapeutic treatment.

Probes may be used in hybridization techniques to detect polynucleotides encoding kallikrein polypeptides. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with probes under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

The detection of polynucleotides encoding kallikrein polypeptides, may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

By way of example, oligonucleotide primers may be employed in a PCR based assay to amplify a portion of polynucleotides encoding kallikrein polypeptides, derived from a sample, wherein the oligonucleotide primers are specific for (i.e. hybridize to) polynucleotides encoding each of the kallikrein polypeptides. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75% and more preferably at least about 90% identity to a portion of polynucleotides encoding kallikrein polypeptides. The primers and probes may be at least 10 nucleotides, and preferably at least 20 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of expression of polynucleotides encoding kallikrein polypeptides. For example, RNA may be isolated from a cell type or tissue known to express these polynucleotides and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomcynski and Sacchi, Anal. Biochem. 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to sets of primers specifically designed against a kallikrein polynucleotide sequence. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with suspected renal cell carcinoma and an individual who is not afflicted with renal cell carcinoma. The reaction may be performed on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-cancerous sample may be considered positive for the presence of renal cell carcinoma.

Oligonucleotides or longer fragments derived from polynucleotides encoding each kallikrein polypeptide may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes. The information from the microarray may be used to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (I 995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

Thus the invention also includes an array comprising polynucleotides encoding kallikrein marker(s). The array can be used to assay expression of kallikrein polynucleotides in the array. The invention allows the quantitation of expression of polynucleotides encoding kallikrein markers.

In an embodiment, the array can be used to monitor the time course of expression of kallikrein polynucleotides in the array. This can occur in various biological contexts such as tumor progression.

The array is also useful for ascertaining differential expression patterns of kallikrein polynucleotides in normal and abnormal cells. This provides a battery of polynucleotides that could serve as molecular targets for diagnosis or therapeutic intervention.

Protein Methods

Binding agents specific for kallikrein polypeptides may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an renal cell

carcinoma in a subject may be determined by (a) contacting a sample from the subject with binding agents for kallikrein polypeptides; (b) detecting in the sample levels of polypeptides that bind to the binding agents; and (c) comparing the levels of polypeptides with a predetermined standard or cut-off value.

5 "Binding agent" refers to a substance such as a polypeptide or antibody that specifically binds to a kallikrein polypeptide. A substance "specifically binds" to a polypeptide if it reacts at a detectable level with the kallikrein polypeptide, and does not react detectably with peptides containing unrelated sequences or sequences of different polypeptides. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al, Develop. Dynamics 197: 1-13, 1993).

10 A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises a kallikrein polypeptide sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example a kallikrein polypeptide sequence may be a peptide portion of a kallikrein polypeptide that is capable of modulating a function mediated by the kallikrein polypeptide.

15 An aptamer includes a DNA or RNA molecule that binds to polynucleotides and polypeptides. An aptamer that binds to a polypeptide (or binding domain) of a kallikrein polypeptide or a polynucleotide encoding a kallikrein polypeptide can be produced using conventional techniques, without undue experimentation. [For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)].

In certain other preferred embodiments, the binding agent is an antibody.

25 In an aspect the present invention provides a diagnostic method for monitoring or diagnosing renal cell carcinoma in a subject by quantitating kallikrein polypeptides, in a biological sample from the subject comprising reacting the sample with antibodies specific for kallikrein polypeptides, which are directly or indirectly labelled with detectable substances, and detecting the detectable substances.

In an aspect of the invention, a method for detecting renal cell carcinoma is provided comprising:

- 30 (a) obtaining a sample suspected of containing kallikrein polypeptides associated with renal cell carcinoma, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) contacting the sample with antibodies that specifically bind kallikrein polypeptides, under conditions effective to bind the antibodies and form complexes;
- (c) measuring the amount of kallikrein polypeptides, present in the sample by quantitating the amount of the complexes; and
- 35 (d) comparing the amount of kallikrein polypeptides, present in the samples with the amount of polypeptides in a control, wherein a change or significant difference in the amount of polypeptides in the sample compared with the amount in the control is indicative of renal cell carcinoma.

In an embodiment, the invention contemplates a method for monitoring the progression of renal cell carcinoma in an individual, comprising:

- (a) contacting antibodies which bind to kallikrein polypeptides, with a sample from the individual so as to form binary complexes comprising each of the antibodies and polypeptides in the sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11;
- (b) determining or detecting the presence or amount of complex formation in the sample;
- (c) repeating steps (a) and (b) at a point later in time; and
- (d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of the stage and/or progression of the renal cell carcinoma in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, renal cell carcinoma at different stages.

Thus, antibodies specifically reactive with a kallikrein polypeptide, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect a kallikrein polypeptide, in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the levels of expression of kallikrein polypeptides, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of kallikrein polypeptides. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on renal cell carcinoma involving kallikrein polypeptides, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of kallikrein polypeptides, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect kallikrein polypeptides, to localize them to particular renal cell carcinoma tumor cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or (Fab)₂ fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F_v molecules (Ladner et al, U.S. Pat. No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant kallikrein

polypeptides may be utilized to prepare antibodies. See, for example, Kohler et al. (1975) *Nature* 256:495-497; Kozbor et al. (1985) *J. Immunol Methods* 81:31-42; Cote et al. (1983) *Proc Natl Acad Sci* 80:2026-2030; and Cole et al. (1984) *Mol Cell Biol* 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) *Science* 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) *Immunochemical Protocols*, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies. The antibodies specific for kallikrein polypeptides used in the methods of the invention may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against kallikrein polypeptides if they bind with a K_a of greater than or equal to 10^{-7} M.

Antibodies that bind to kallikrein polypeptides may be labelled with a detectable substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g., ^3H , ^{14}C , ^{35}S , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a kallikrein polypeptide. The second antibody may be labeled with a detectable substance to detect the primary antigen-antibody reaction. By way of example, if the antibody having specificity against a kallikrein polypeptide is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect kallikrein polypeptides. Generally, antibodies may be labeled with detectable substances and kallikrein polypeptides, may be localised in tissues and cells based upon the presence of the detectable substance.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies) for kallikrein polypeptides may be immobilized on a carrier or support. Examples of suitable carriers or

supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized material may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. Binding agents (e.g. antibodies) may be indirectly immobilized using second binding agents specific for the first binding agent. For example, mouse antibodies specific for a kallikrein polypeptide may be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where radioactive labels are used as a detectable substance, kallikrein polypeptides may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

Therefore, in accordance with an embodiment of the invention, a method is provided wherein antibodies specific for each kallikrein polypeptide, are labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of the enzymes and substrates, form fluorescent complexes with lanthanide metals. Lanthanide metals are added and the kallikrein polypeptides are quantitated in the sample by measuring fluorescence of the fluorescent complexes. Antibodies specific for the kallikrein polypeptides may be directly or indirectly labelled with enzymes. Enzymes are selected based on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Examples of suitable enzymes include alkaline phosphatase and β -galactosidase.

Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

Antibodies specific for kallikrein polypeptides may also be indirectly labelled with enzymes. For example, an antibody may be conjugated to one partner of a ligand binding pair, and the enzyme may be coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In another embodiment, antibodies specific for the anti-kallikrein antibodies are labeled with an enzyme.

In accordance with an embodiment, the present invention provides means for determining kallikrein polypeptides in a sample, in particular a serum sample, by measuring kallikrein polypeptides by

immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure kallikrein polypeptides in serum. In general, an immunoassay method may be competitive or noncompetitive. Competitive methods typically employ immobilized or immobilizable antibodies to the kallikrein polypeptides and a labeled form of each of the kallikrein polypeptides. Kallikrein polypeptides and labeled kallikrein polypeptides compete for binding to anti-kallikrein antibodies. After separation of the resulting labeled kallikrein polypeptides that have become bound to anti-kallikrein polypeptides (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the amount of kallikrein polypeptides, in the test sample in any conventional manner, e.g., by comparison to a standard curve.

In an aspect, a non-competitive method is used for the determination of kallikrein polypeptides with the most common method being the "sandwich" method. In this assay, two types of antibodies specific for kallikrein polypeptides are employed. One type of antibody is directly or indirectly labeled (sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or sequentially with a test sample. Sequential methods can be accomplished by incubating capture antibodies with the sample, and adding the detection antibodies at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibodies can be incubated with the sample first and then the capture antibodies added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to complete the assay, the capture antibodies are separated from the liquid test mixture, and labels are measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally the labels are measured in the capture antibody phase since it comprises kallikrein polypeptides bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

In a typical two-site immunometric assay for kallikrein polypeptides, one or both of the capture and detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The labels used with the detection antibodies can be selected from any of those known conventionally in the art. The labels may be an enzyme or a chemiluminescent moiety, but it can also be a radioactive isotope, a fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the ligand), and the like. Preferably antibodies are labelled with enzymes which are detected by adding substrates that are selected so that a reaction product of the enzymes and substrates forms fluorescent complexes. Capture antibodies may be selected so that they provide a means for being separated from the remainder of the test mixture. Accordingly, the capture antibodies can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables immobilization to be accomplished subsequent to introduction of the capture antibodies to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by

contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, a capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

A particular sandwich immunoassay method of the invention employs two types of antibodies, first
5 antibodies are reactive against kallikrein polypeptides and second antibodies having specificity against antibodies reactive against kallikrein polypeptides labelled with enzymatic labels, and fluorogenic substrates for the enzymes. An enzyme may be alkaline phosphatase (ALP) and the substrate is 5-fluorosalicyl phosphate. ALP cleaves phosphate out of the fluorogenic substrate, 5-fluorosalicyl phosphate, to produce 5-fluorosalicylic acid (FSA). 5-Fluorosalicylic acid can then form a highly fluorescent ternary complex of the
10 form FSA-Tb(3+)-EDTA, which can be quantified by measuring the Tb3+ fluorescence in a time-resolved mode. Fluorescence intensity is measured using a time-resolved fluorometer as described herein.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

Computer Systems

15 Computer readable media comprising kallikrein markers is also provided. "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the invention contemplates computer readable
20 medium having recorded thereon markers identified for patients and controls.

"Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on kallikrein markers.

A variety of data processor programs and formats can be used to store information on kallikrein
25 markers on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

30 By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

The invention provides a medium for holding instructions for performing a method for determining
35 whether a patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the patient has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention also provides in an electronic system and/or in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising determining the presence or absence of kallikrein markers or polynucleotides encoding same, and based on the presence or absence of the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma, and optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention further provides in a network, a method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring information from the network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information and information on the kallikrein markers or polynucleotides encoding same, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

The invention still further provides a system for identifying selected records that identify a renal cell carcinoma cell. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising kallikrein markers, or polynucleotides encoding same, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting a renal cell carcinoma cell using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

- (a) creating records of kallikrein markers or polynucleotides encoding same, isolated from a sample suspected of containing an renal cell carcinoma cell;
- (b) providing a database comprising records of data comprising kallikrein markers, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and/or comprising polynucleotides encoding same; and
- (c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a positive indication that the markers of step (a) have been isolated from a cell that is a renal cell carcinoma cell.

The invention contemplates a business method for determining whether a subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma associated with kallikrein markers or polynucleotides encoding same comprising: (a) receiving phenotypic information on the subject and information on kallikrein markers or polynucleotides encoding same, associated with samples from the subject; (b) acquiring

information from a network corresponding to the kallikrein markers or polynucleotides encoding same; and (c) based on the phenotypic information, information on the kallikrein markers or polynucleotides encoding same, and acquired information, determining whether the subject has renal cell carcinoma or a pre-disposition to renal cell carcinoma; and (d) optionally recommending treatment for the renal cell carcinoma or pre-renal cell carcinoma condition.

Imaging Methods

Antibodies specific for kallikrein polypeptides may also be used in imaging methodologies in the management of renal cell carcinoma. The invention provides a method for imaging tumors associated with kallikrein polypeptides.

In an embodiment the method is an *in vivo* method and a subject or patient is administered imaging agents that carry imaging labels and are capable of targeting or binding to kallikrein polypeptides. In the method each imaging agent is labeled so that it can be distinguished during the imaging. The imaging agents are allowed to incubate *in vivo* and bind to the kallikrein polypeptides associated with renal cell carcinoma tumors. The presence of label is localized to the renal cell carcinoma, and the localized label is detected using imaging devices known to those skilled in the art.

The imaging agents may be antibodies or chemical entities that recognize kallikrein polypeptides. In an aspect of the invention an imaging agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for kallikrein polypeptides used in the methods of the invention may be obtained from scientific or commercial sources, or isolated native or recombinant kallikrein polypeptides may be utilized to prepare antibodies etc as described herein.

An imaging agent may be a peptide that mimics the epitope for an antibody specific for a kallikrein polypeptide and binds to a kallikrein polypeptide. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes tyrosine, lysine, or phenylalanine to which N_2S_2 chelate is complexed (See U.S. Patent No. 4,897,255). The anti-kallikrein peptide conjugate is then combined with a radiolabel (e.g. sodium ^{99m}Tc pertechnetate or sodium ^{188}Re perrhenate) and it may be used to locate a tumor producing the kallikrein polypeptides.

Imaging agents carry labels to image the kallikrein polypeptides. Agents may be labelled for use in radionuclide imaging. In particular, agents may be directly or indirectly labelled with a radioisotope. Examples of radioisotopes that may be used in the present invention are the following: ^{277}Ac , ^{211}At , ^{128}Ba , ^{131}Ba , 7Be , ^{204}Bi , ^{205}Bi , ^{206}Bi , ^{76}Br , ^{77}Br , ^{82}Br , ^{109}Cd , ^{47}Ca , ^{11}C , ^{14}C , ^{36}Cl , ^{48}Cr , ^{51}Cr , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{165}Dy , ^{155}Eu , ^{18}F , ^{153}Gd , ^{66}Ga , ^{67}Ga , ^{68}Ga , ^{72}Ga , ^{198}Au , 3H , ^{166}Ho , ^{111}In , ^{113m}In , ^{115m}In , ^{123}I , ^{125}I , ^{131}I , ^{189}Ir , ^{191m}Ir , ^{192}Ir , ^{194}Ir , ^{52}Fe , ^{55}Fe , ^{59}Fe , ^{177}Lu , ^{15}O , $^{191m-191}Os$, ^{109}Pd , ^{32}P , ^{33}P , ^{42}K , ^{226}Ra , ^{186}Re , ^{188}Re , ^{82m}Rb , ^{153}Sm , ^{46}Sc , ^{47}Sc , ^{72}Se , ^{75}Se , ^{105}Ag , ^{22}Na , ^{24}Na , ^{89}Sr , ^{35}S , ^{38}S , ^{177}Ta , ^{96}Tc , ^{99m}Tc , ^{201}Tl , ^{202}Tl , ^{113}Sn , ^{117m}Sn , ^{121}Sn , ^{166}Yb , ^{169}Yb , ^{175}Yb , ^{88}Y , ^{90}Y , ^{62}Zn and ^{65}Zn . Preferably the radioisotope is ^{131}I , ^{125}I , ^{123}I , ^{111}I , ^{99m}Tc , ^{90}Y , ^{186}Re , ^{188}Re , ^{32}P , ^{153}Sm , ^{67}Ga , ^{201}Tl , ^{77}Br , or ^{18}F , and it is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling,

and ^{35}S labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, Nature 144:945 (1962), David et al., Biochemistry 13:1014-1021 (1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., Biochem. J. 89:114-123 (1963); Marchalonis, J., Biochem. J. 113:299-305 (1969); and Morrison, M. et al., Immunochemistry, 289-297 (1971). $^{99\text{m}}\text{Tc}$ -labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S. Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for ^{111}In -labeling biological agents are described by Hnatowich, D. J. et al., J. Immunol. Methods, 65:147-157 (1983), Hnatowich, D. et al., J. Applied Radiation, 35:554-557 (1984), and Buckley, R. G. et al., F.E.B.S. 166:202-204 (1984).

15 An imaging agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo* method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

20 In the case of radiolabeled agents, the agents may be administered to the patient, localized to the tumor having one or more kallikrein polypeptides with which the agents bind, and detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using, for example, a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g., ^{11}C , ^{18}F , ^{15}O , and ^{13}N).

30 Whole body imaging techniques using radioisotope labeled agents can be used for locating both primary tumors and tumors which have metastasized. Antibodies specific for kallikrein polypeptides or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For renal cell carcinoma, administration preferably is intravenous. The bio-distribution of the labels can be monitored by scintigraphy, and accumulations of the labels can be related to the presence of renal cell carcinoma cells. Whole body imaging techniques are described in U.S. Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis, staging and visualization of cancer, in particular renal cell carcinoma, so that surgical and/or radiation treatment protocols can be used more efficiently.

Screening Methods

The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit renal cell carcinoma or potentially contribute to renal cell carcinoma. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)2, and Fab expression library fragments, and epitope-binding fragments thereof)], nucleic acids (e.g. antisense, interference RNA) and small organic or inorganic molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing:

- (a) levels of kallikrein markers or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and
- (b) levels of the kallikrein markers or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of kallikrein markers or polynucleotides encoding same in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

In an aspect, the invention provides a method of selecting an agent for inhibiting renal cell carcinoma in a patient comprising:

- (a) obtaining a sample comprising cancer cells from the patient;
- (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;
- (c) comparing kallikrein markers and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
- (d) selecting one of the test agents which alters the levels of the kallikrein markers and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery business comprising:

- (a) providing one or more methods or assay systems for identifying agents that inhibit renal cell carcinoma in a patient;
- (b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and

- 24 -

- (c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as having an acceptable therapeutic profile.

In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the renal cell carcinoma carcinogenic potential of a test compound comprising:

- (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and
- (b) comparing kallikrein markers and/or polynucleotides encoding same in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses renal cell carcinoma carcinogenic potential.

Kits

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least kallikrein polynucleotides or binding agents (e.g. antibodies) described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients, and to screen and identify those individuals afflicted with or exhibiting a predisposition to renal cell carcinoma.

Thus, the invention also contemplates kits for carrying out the methods of the invention. Such kits typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

In an embodiment, a container with a kit comprises binding agents as described herein. By way of example, the kit may contain antibodies specific for kallikrein polypeptides, antibodies against the antibodies labelled with enzymes, and substrates for the enzymes. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

In an aspect of the invention, the kit includes antibodies or antibody fragments which bind specifically to epitopes of kallikrein polypeptides, and means for detecting binding of the antibodies to epitopes associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents. Containers that provide a formulation for direct use, usually do not require other reagents, as for example, where the kit contains radiolabelled antibody preparations for *in vivo* imaging.

A kit may be designed to detect the level of polynucleotides encoding kallikrein polypeptides in a sample. Such kits generally comprise oligonucleotide probes or primers, as described herein, that hybridize to polynucleotides encoding kallikrein polypeptides. Such oligonucleotides may be used, for example, within

a PCR or hybridization procedure. Additional components that may be present within the kits include second oligonucleotides and/or diagnostic reagents to facilitate detection of polynucleotides encoding kallikrein polypeptides.

5 The reagents suitable for applying the screening methods of the invention to evaluate compounds may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

Applications

Kallikrein polypeptides are targets for renal cell carcinoma immunotherapy. Such immunotherapeutic methods include the use of antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

10 In one aspect, the invention provides antibodies specific for kallikrein polypeptides that may be used systemically to treat renal cell carcinoma. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue. Thus, the invention provides a method of treating a patient susceptible to, or having a cancer that expresses kallikrein polypeptides comprising administering to the patient an effective amount of antibodies that bind specifically to kallikrein polypeptides. In another aspect, the invention provides a method of inhibiting the growth of tumor cells expressing kallikrein polypeptides, comprising administering to a patient antibodies which bind specifically to kallikrein polypeptides in amounts effective to inhibit growth of the tumor cells. Antibodies specific for kallikrein polypeptides may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing kallikrein polypeptides comprising reacting antibody immunoconjugates or immunotoxins with the cell in an amount sufficient to inhibit the growth of, or kill the cell.

20 By way of example, unconjugated antibodies specific for kallikrein polypeptides may be introduced into a patient such that the antibodies bind to cancer cells expressing kallikrein polypeptides and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may include complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, altering the physiologic function of kallikrein polypeptides and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies, antibodies specific for kallikrein polypeptides, conjugated to therapeutic agents (e.g. immunoconjugates) may also be used therapeutically to deliver the agents directly to tumor cells expressing kallikrein polypeptides and thereby destroy the tumor. Examples of such agents include abrin, 30 ricin A, *Pseudomonas* exotoxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

35 Cancer immunotherapy using antibodies specific for kallikrein polypeptides may utilize the various approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlen et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunther Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54:

6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

5 In the practice of a method of the invention, antibodies specific for kallikrein polypeptides capable of inhibiting the growth of cancer cells expressing kallikrein polypeptides are administered in a therapeutically effective amount to cancer patients whose tumors express or overexpress kallikrein polypeptides. The invention may provide a specific, effective and long-needed treatment for renal cell carcinoma. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

10 Patients may be evaluated for the presence and levels of kallikrein polypeptides expression and overexpression in tumors, preferably using immunohistochemical assessments of tumor tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of kallikrein polypeptides. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

15 Antibodies specific for kallikrein polypeptides useful in treating cancer include those that are capable of initiating a potent immune response against the tumor and those that are capable of direct cytotoxicity. In this regard, the antibodies may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, antibodies specific for kallikrein polypeptides that exert a direct biological effect on tumor growth
20 are useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent
25 macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

The anti-tumor activity of a combination of antibodies specific for kallikrein polypeptides may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, wherein human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

30 The methods of the invention contemplate the administration of combinations, or "cocktails" of different individual antibodies recognizing epitopes of kallikrein polypeptides. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects. In addition, the
35 administration of the antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

The antibodies specific for kallikrein polypeptides used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the anti-tumor function of the antibodies and is non-reactive with the subject's immune systems. Examples
5 include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16^{sup}.th Edition, A. Osal., Ed., 1980).

Antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Routes of administration include, but are not limited to, intravenous, intraperitoneal,
10 intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

Treatment will generally involve the repeated administration of the antibody preparation via an
15 acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will depend upon various factors generally appreciated by those of skill in the art, including the type of cancer and the severity, grade, or stage of the cancer, the binding affinity and half life of the antibodies used, the degree of expression of kallikrein polypeptides in the patient, the extent of circulating kallikrein polypeptide antigens the desired steady-state antibody concentration level, frequency of treatment, and the influence of
20 any chemotherapeutic agents used in combination with a treatment method of the invention.

Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies per week may be effective and well tolerated, although even higher weekly doses may be appropriate and/or well tolerated. A determining factor in defining the appropriate dose is the amount of antibodies necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve
25 tumor inhibition or regression. Direct administration of antibodies specific for kallikrein polypeptides is also possible and may have advantages in certain situations.

Patients may be evaluated for kallikrein polypeptides, preferably in serum, in order to assist in the determination of the most effective dosing regimen and related factors. The assay methods described herein, or similar assays, may be used for quantitating circulating kallikrein polypeptide levels in patients prior to
30 treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters, such as serum kallikrein polypeptides.

The invention further provides vaccines formulated to contain kallikrein polypeptides or fragments thereof. The use in anti-cancer therapy of tumor antigens in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human
35 PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These methods can be practiced by employing kallikrein polypeptides, or fragments thereof, or polynucleotides and recombinant vectors capable of expressing and appropriately presenting the kallikrein immunogens.

By way of example, viral gene delivery systems may be used to deliver polynucleotides encoding kallikrein polypeptides. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding kallikrein polypeptides, or fragments thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present kallikrein antigens to a patient's immune system. For example, autologous dendritic cells which express MHC class I and II, may be pulsed with kallikrein polypeptides, or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate renal cell carcinoma patients' immune systems (See, for example, Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380).

Anti-idiotypic antibodies specific for kallikrein polypeptides can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing the polypeptides. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic antibodies that mimic an epitope on a kallikrein polypeptide (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such antibodies can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing kallikrein polypeptides. Constructs comprising DNA encoding kallikrein polypeptides/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded kallikrein polypeptides/immunogens. The polypeptides/immunogens may be expressed as cell surface proteins or be secreted. Expression of the polypeptides/immunogens results in the generation of prophylactic or therapeutic humoral and cellular immunity against the cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing kallikrein polypeptides. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that the kallikrein polypeptides form a complex with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing kallikrein polypeptides by reacting a combination of the immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver polynucleotides encoding kallikrein polypeptides to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct

recombinant vectors that will express antisense nucleic acid molecules for kallikrein polypeptides. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Genes encoding kallikrein polypeptides can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired kallikrein polypeptide-encoding fragments. Such constructs can
5 inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of genes encoding kallikrein polypeptides, i.e., the promoters, enhancers, and
10 introns. Preferably, oligonucleotides are derived from the transcription initiation site, e.g. between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory
15 molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme
20 molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding kallikrein polypeptides.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides
25 corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and
30 which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Kallikrein polypeptides and polynucleotides encoding the polypeptides, and fragments thereof,
35 antibodies, and/or agents identified using a method of the invention, or combinations thereof, may be used in the treatment of renal cell carcinoma or diseases, conditions or syndromes associated with renal cell carcinoma, in a subject. The kallikrein polypeptides, polynucleotides, and agents may be formulated into compositions for administration to subjects suffering from renal cell carcinoma. Therefore, the present invention also relates to a composition comprising kallikrein polypeptides, or polynucleotides encoding the

polypeptides, or a fragment thereof, or an agent identified using a method of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing renal cell carcinoma in a subject is also provided comprising administering to a patient in need thereof, kallikrein polypeptides, or polynucleotides encoding the polypeptides, an agent identified in accordance with a method
5 of the invention, or a composition of the invention.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the
10 substance.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's
15 Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other
20 therapeutic agents or other forms of treatment (e.g. chemotherapy or radiotherapy). The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The following non-limiting examples are illustrative of the present invention:

Example 1

25 Human kallikreins 5, 6, 10, and 11 (hK5,/6/10/11) are expressed by many normal tissues and it has been suggested that they may represent candidate cancer diagnostic/prognostic markers. Renal cell carcinoma (RCC) is characterized by unpredictable outcome, despite the use of conventional prognostic factors. The immunohistochemical expression (IE) and the predictive value of the above kallikreins was evaluated in RCC. Included in the study were 95 patients who underwent radical nephrectomy for RCC. The
30 median follow-up was 60 (1-180) months. Fifty seven of the 95 RCC cases were immunostained for hK5, 70/95 for hK6, 70/95 for hK10, and 69/95 for hK11, respectively. The immunohistochemical method of streptavidin-biotin-peroxidase using anti-hK5, /6/10/11 monoclonal and polyclonal antibodies was performed. The IE of all kallikreins was correlated with tumor size, histological type, histological malignancy, mitotic index, and pathological stage. The Fuhrman 4-scale grading system was used for the
35 determination of the histological malignancy. For statistical analysis, four grades were collapsed into two and RCC cases were categorized as low and high malignant (LM and HM) respectively. Statistical analysis included Pearson Chi-square and Kruskal Wallis tests. Survival data were analyzed using Kaplan-Meier and Cox regression analysis. A Pvalue < 0.05 was considered significant. In the normal (adjacent to tumor) renal parenchyma, the epithelium of the urinary tubuli showed a cytoplasmic IE of all kallikreins. In RCC, their IE

was decreased: 33/57 cases (58%) were positive for hK5, 27/70 (39%) for hK6, 46/70 (66%) for hK10 and 32/69 (46%) for hK11, respectively. A statistically significant positive correlation was observed among the IE of all kallikreins. HM-RCC expressed all kallikreins in a higher percentage than LM-RCC, but a statistically significant difference was observed only in the case of hK6 and hK10 (55% vs. 27%, $p=0.016$ and 79% vs. 56%, $p=0.044$ respectively). Hk6 and hK11 showed a positive correlation with pathological stage: hK6 with both Robson and TNM 1997 staging systems ($p=0.010$ and $p=0.017$ respectively), and hK11 only with the Robson staging system ($p=0.045$). In both the Kaplan-Meier and the univariate Cox regression analysis, hK6 IE showed a negative correlation with disease survival ($p=0.05$ and $p=0.038$ respectively). In univariate analysis, nuclear grade, Robson and TNM staging systems correlated with disease survival as well. However, in the multivariate analysis, TNM staging system was the only independent prognostic factor. In conclusion, although the IE of hK5/6/10/11 is down-regulated in RCC, tumors of high grade and/or advanced stage express one or more of the above kallikreins in a higher percentage. It seems that hK6 may significantly contribute to information in predicting poor disease outcome for RCC.

The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the domains, cell lines, vectors, methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Below full citations are set out for the references referred to in the specification.

Table 1

Kallikrein Polypeptide	Kallikrein Nucleic Acid Designation	GenBank Accession No.
Kallikrein 5	KLK5	AAF03101, AF135028 (mRNA join 2101..2131, 2210..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11570) (CDS join 2221..2293, 4762..5023, 5763..6019, 6105..6238, 11092..11247), AF168768 (CDS 170..1051)
Kallikrein 6	KLK6	AFB66483, AF013988 (CDS 174..881), AF149289 (CDS 3567..3606, 4346..4502, 8211..8369, 9791..9927, 11805..11954) (mRNA join 2001..2185, 3084..3135, 3559..3606, 4346..4502, 8122..8369, 9791..9927, 11805..11957), HSU62801 (CDS 246..980)
Kallikrein 10	KLK10	AAC14266, AF055481 (CDS 614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945) (mRNA join 48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474), NM_002776 (CDS 220..1050)
Kallikrein 11	KLK11	BAA33404, AAD47815, AB012917 (CDS 26..874), AF164623 (CDS 4224..4263, 5061..5217, 5545..5810, 6627..6727..6763, 7158..7307) (mRNA join 2312..2398, 4189..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7310)

We Claim:

1. A method for detecting kallikrein polypeptides or polynucleotides encoding kallikrein polypeptides that are associated with renal cell carcinoma in a patient comprising:
 - 5 (a) taking a sample from a patient;
 - (b) detecting or identifying in the sample one or more kallikrein polypeptides or polynucleotides encoding the kallikrein polypeptides wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11 ; and
 - 10 (c) comparing the detected amount with an amount detected for a standard.
2. A method for detecting kallikrein polypeptides associated with renal cell carcinoma in a patient comprising:
 - (a) obtaining a sample from a patient;
 - 15 (b) detecting in the sample one or more kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
 - (c) comparing the detected amounts with amounts detected for a standard.
3. A method for diagnosing and monitoring renal cell carcinoma in a subject comprising detecting in a sample from the subject one or more kallikrein polypeptides, wherein the kallikrein polypeptides
20 comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
4. A method as claimed in claim 1, 2 or 3 wherein the kallikrein polypeptides are detected using antibodies that bind to the kallikrein polypeptides or parts thereof
5. A method of detecting renal cell carcinoma in a patient, the method comprising comparing:
 - 25 (a) levels of kallikrein polypeptides in a sample from the patient, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and
 - (b) normal levels of expression of the kallikrein polypeptides in a control sample, wherein a significant difference in levels of kallikrein polypeptides, relative to the corresponding
30 normal levels, is indicative of renal cell carcinoma.
6. A method of any proceeding claim where the levels of kallikrein polypeptides are higher than normal levels and are indicative of advance disease and/or poor prognosis.
7. A method for monitoring the progression of renal cell carcinoma in a patient, the method comprising: (a) detecting in a sample from the patient at a first time point, kallikrein polypeptides,
35 wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of renal cell carcinoma.

8. A method for determining in a patient whether renal cell carcinoma has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels or non-metastatic levels of the kallikrein polypeptides, in a control sample wherein a significant difference between the levels of expression in the patient sample and the normal levels or non-metastatic levels is an indication that the renal cell carcinoma has metastasized.
9. A method for assessing the aggressiveness or indolence of renal cell carcinoma comprising comparing: (a) levels of expression of kallikrein polypeptides, in a patient sample, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) normal levels of expression of the kallikrein polypeptides, in a control sample, wherein a significant difference between the levels in the patient sample and normal levels is an indication that the cancer is aggressive or indolent.
10. A method for diagnosing and monitoring renal cell carcinoma in a sample from a subject comprising isolating polynucleotides from the sample, and detecting in the sample polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein.
11. A method as claimed in claim 10 wherein significant differences in the levels of the polynucleotides in the sample compared to a control is indicative of disease, disease stage, stage, and/or prognosis.
12. A method for determining the presence or absence of renal cell carcinoma in a subject comprising: (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides encoding kallikrein polypeptides relative to a predetermined cut-off value, and therefrom determining the presence or absence of renal cell carcinoma in the subject.
13. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the levels of nucleic acids are detected by polymerase chain reaction.
14. A method as claimed in claim 12, wherein the nucleic acids are mRNA and the amounts of mRNA are detected using a hybridization technique, employing oligonucleotide probes that hybridize to kallikrein polypeptides.
15. A method for assessing the potential efficacy of a test agent for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides, and/or polynucleotides encoding same in a first sample obtained from a patient and exposed to the test agent, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides encoding same in the first sample,

- relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting renal cell carcinoma in the patient.
16. A method of claim 15 wherein the first and second samples are portions of a single sample obtained from the patient.
- 5 17. A method of claim 15 wherein the first and second samples are portions of pooled samples obtained from the patient.
18. A method of assessing the efficacy of a therapy for inhibiting renal cell carcinoma in a patient, the method comprising comparing: (a) levels of kallikrein polypeptides and/or polynucleotides encoding same in a first sample obtained from the patient, wherein the kallikrein polypeptides
10 comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein polypeptides and/or polynucleotides encoding same in a second sample obtained from the patient following therapy, wherein a significant difference in the levels of expression of the kallikrein polypeptides and/or polynucleotides in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting renal cell
15 carcinoma in the patient.
19. A method of selecting an agent for inhibiting renal cell carcinoma in a patient the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein
20 polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) selecting one of the test agents which alters the levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.
20. A method of inhibiting renal cell carcinoma in a patient, the method comprising (a) obtaining a
25 sample comprising cancer cells from the patient; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of kallikrein polypeptides and/or polynucleotides encoding same in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11; and (d) administering to the patient at least one of the test agents which alters the
30 levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot containing that test agent, relative to other test agents.
21. A method of assessing the renal cell carcinoma cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of renal cell carcinoma cells in the presence and absence of the test compound; and (b) comparing expression of kallikrein polypeptides and/or
35 polynucleotides encoding same, in each of the aliquots, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11, and wherein a significant difference in levels of kallikrein polypeptides and/or polynucleotides encoding same in the aliquot maintained in the presence of the test compound,

relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses renal cell carcinoma cell carcinogenic potential.

22. An *in vivo* method for imaging renal cell carcinoma comprising:
- 5 (a) injecting a patient with agents that bind to kallikrein polypeptides, the agents carrying labels for imaging the renal cell carcinoma, and wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11;
- (b) allowing the agents to incubate *in vivo* and bind to the kallikrein polypeptides; and
- (c) detecting the presence of the labels localized to the renal cell carcinoma.
- 10 23. A method of inhibiting renal cell carcinoma in a patient at risk for developing renal cell carcinoma, the method comprising inhibiting expression of genes encoding kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10 and kallikrein 11.
24. A method of any preceding claim comprising at least two of the kallikrein polypeptides.
- 15 25. A method of any preceding claim comprising at least three of the kallikrein polypeptides.
26. A method of claim 22 where the kallikrein polypeptides are kallikrein 6 and kallikrein 11.
27. A method of any preceding claim wherein the patient sample comprises serum obtained from the patient.
28. A kit for carrying out a method as claimed in any preceding claim.
- 20 29. A kit for assessing whether a patient is afflicted with renal cell carcinoma, the kit comprising reagents that specifically bind with kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
30. A kit for assessing the suitability of each of a plurality of agents for inhibiting renal cell carcinoma in a patient, the kit comprising: (a) the plurality of agents; and (b) reagents for detecting kallikrein polypeptides, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 10, and kallikrein 11.
- 25 31. A kit as claimed in claim 28 or 29 wherein the reagents are antibodies that specifically bind with protein or protein fragments corresponding to kallikrein polypeptides.
- 30

Sequence Listing**SEQ ID NO. 1**

hk5 amino acid

5

MATARPPWMWVLCALITALLLGVTEHVLANNNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGS
 CDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMFQGVKSIPHPG
 YSHPGHSNDLMLIKLNRIRPTKDVRPINVSSHCPISAGTKCLVSGWGTTKSPQVHFVKVLQCLNISVLSQKR
 CEDAYPRQIDDTMFCAGDKAGRDSCQGDSSGGPVVCSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQET
 IQANS

10

SEQ ID NO. 2

KLK5 CDS

ggtgtctgtg cgtcctgcac ccacatcttt ctctgtcccc tccttgccct gtctggaggg
 15 tgctagactc ctatcttctg aattctatag tgccctgggtc tcagcgaggt gccgatgggtg
 gcccgctcctt gtgggttcctc tctacttggg gaaatcaggt gcagcggcca tggctacagc
 aagacccccc tggatgtggg tgctctgtgc tctgacaca gccttgcttc tgggggtcac
 agagcatgtt ctgcgcaaca atgatgtttc ctgtgaccac ccctctaaca ccgtgccctc
 tgggagcaac caggacctgg gagctggggc cggggaagac gcccggtcgg atgacagcag
 20 cagccgcac atcaatggat ccgactgcga tatgcacacc cagccgtggc aggccggcgt
 gttgctaagg cccaaccagc tctactgcgg ggccgtgttg gtgcattccac agtggctgct
 cacggccggc cactgcagga agaaagtctt cagagtccgt ctccggccact actccctgtc
 accagtctat gaatctgggc agcagatggt ccagggggtc aaatccatcc cccacccctg
 ctactccac cctggccact ctaacgacct catgctcatc aaactgaaca gaagaattcg
 25 tcccactaaa gatgtcagac ccactcaact ctctctcat tgtccctctg ctgggacaaa
 gtgcttggtg tctggctggg ggacaaccaa gagccccaa gtgcacttcc ctaaggctcc
 ccagtgcctt aatatcagcg tgctaagtca gaaaaggtgc gaggatgctt acccgagaca
 gatagatgac accatgttct gcgcgggtga caaagcaggt agagactcct gccagggtga
 ttctgggggg cctgtggtct gcaatggctc cctgcaggga ctctgtcctt ggggagatta
 30 cccttgtgcc cggcccaaca gaccgggtgt ctacacgaac ctctgcaagt tcaccaagt
 gatccaggaa accatccagg ccaactcctg agtcatccca ggactcagca cacccgcac
 cccacctgct gcaggacag ccctgacact cctttcagac cctcattcct tcccagagat
 gttgagaatg ttcattctct cagccctga ccccatgtct cctggactca gggctctgct
 cccccacatt gggctgaccg tgtctctcta gttgaacctt gggaacaatt tccaaaactg
 35 tccagggcgg ggggtgctc tcaatctccc tggggcactt tcatcctcaa gctcagggcc
 catcccttct ctgcagctct gacccaaatt tagtcccaga aataaactga gaagtggaaa
 aaaaaaa

40

SEQ ID NO. 3

KLK5 nucleic acid

gggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt ggcttgagtc
 tcccctgcct aaaatgcagg gagaggagg cagaaagaca gggaagagga aggggtgggg
 45 aagaaagaga gagagagaga gagacagaat aacacaacta cagaaacaca gagagaacac
 acagagagcc tgggacacag ggacacacag agtcagagag aaaagagaag atagagaaag
 acacaaatgg agacacagag gtgtaaagaa agagagatta acagagtccc agatacacgc
 aaaggggcag aagcacagtt ttcagggttg tgtctatgat catcttcttt tttttttttt
 50 tttttttttt tttttgagac ggagtctcgc tctgtcggcc aggttgaggt gcagtggcgg
 gatctcggct cactgcaagc tccgcctccc gggttcacgc cattctcctg cctcagcctc
 ccaagttagct gggactacag gcgcctgcc ctacgcccgg ctaatttttt tgtattttta
 gtagagacgg ggtttcaccg ttttagccgg gatggcctcg atctcctgac ctctgatcc
 gccgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccgag cccggccatg
 atcatcttct tgactatgct gatgtgacaa gtacctaaag ccatcagact ctacccttta
 55 aatatgcagt ttggggcagg caccgtggct catgcctgta attccagcac tttgggaggg
 agagggtgggt gaatcacttg aggccaggag tttgagacca gcctggccaa catggtgaaa

	ctctgtcttt	actaaaaaaaa	aaaaaaaaaaa	aaaaaaaaaatc	agccgggtgt	cgtggggcac
	acctgtaatc	ccagctatgc	tggaggctga	ggcacgagag	tcacttgaac	cctggaggcg
	gaggttgtag	tgggcccaga	tcacatcacc	gccctccagc	ctgggcgaca	gagcaagact
	ctgtctcaaa	taaataaata	aacaaacgaa	caagcagttt	gttgtagctt	agttatatct
5	aaaaaaaaaaa	tgctgtcaac	aaatagagca	gaagtgaat	aaaggaaaaat	aaatggggcca
	agaactctaa	ggtatatattg	acaaatcatt	cagaaccttt	aaaaaagaaa	gaatcacaga
	ggcatagaaa	gacagggagg	aacagggaga	cagaaacacc	tgtggcccaa	ggagaacaaa
	acaaggctcc	taagacagac	aggaggagag	agagagagag	tgagttagag	acagacagag
	aaaaagacag	agagagagag	acagagacag	agagacagag	aggcgagagg	gatagaaaga
10	gagagagggg	tggagagaga	cacgagatat	tgagagagac	tcagaaagat	agccgagggg
	gaaccacaga	gagatggaag	aagactctga	gaaaaaacca	gagacaaaga	tggaaaagagg
	agtatcgagg	gtgaacagac	agtgggtgga	tgagcaaaat	gcagagaaga	aagcaagcaa
	tccaggcgcc	aagaatagtg	accagaggtt	ggtgagaagc	cagatcctta	aggctggggg
	aggcagggaa	ggggctggcc	tggcttccgg	agacccctcc	ccattctccg	ggccagggag
15	gtagggagtg	acattccgga	ctgggtgggg	ggtgctctgg	gggtggagat	agggggagca
	ggaggagcta	ttgctaaggc	ccgataggca	cctcattgcc	cgggaatgtg	cccaggggag
	cagtgggtgg	ttataactca	ggcccggtgc	ccagagccca	ggaggaggca	gtggccagga
	aggcacaggc	ctgagaagtc	tgccgctgag	ctgggagcaa	atccccacc	ccctacctgg
	gggacagggc	aagttagacc	tggtaggggt	ggctcagcag	gcagggaagg	agaggtgtct
20	gtgcgtcctg	caccacatc	tttctctgtc	ccctccttgc	cctgtctgga	ggctgtctga
	ctcctatctt	ctgaattcta	tagtgccctg	gtctcagcgc	agtgccgatg	gtggcccgtc
	cttgtggttc	ctctctacct	ggggaataa	ggtaggggag	ggaggggaag	tgggttaagg
	gtccccgga	tcgcctgggc	ctcccaacc	ctgacattc	cccatccagg	gtcagcgcc
	atggctacag	caagaccccc	ctggatgtgg	gtgctctgtg	ctctgatcac	agccttgctt
25	ctgggggtca	caggtaacca	gaactctggg	gtgggagggg	tgtgggattg	ggaggactgt
	ctctgcggca	ctagagcgcc	tgtccccctg	ggaactgtgt	gagcctgggc	atgactccgg
	gaccgggtga	atgtgagctc	ctgtctgtac	ttgtggttgt	gcgatcgtat	gtggccctgt
	gactgccacg	gtgtgtgtcg	gggaggggga	tgcccttttc	catatcaggt	gactgtgcgg
	caggtggcac	tgaccctttg	aggctgtgtg	tgtgtgtttg	tgatttgtgt	tgactttaag
30	atttgtgtgtg	gtccacagc	tgtgtgtgtg	aatgcatgta	gcactggggg	tgcttactgt
	gtgtttggct	gtgtgtgtgtg	acttggcatt	gtatatgact	gcaggtatct	gcagttcctg
	tccctgaggt	cccgggattg	cgtgcaacaa	aagtggctcat	caccatggaa	agctgtgact
	gtgtgctgct	tgaggcgat	tatgtgattg	tggtgagtg	tgacgttatg	gatgcccgta
	tttgtgaccg	tgtgactacc	tgaagctctg	tgtaggggtg	actgtatgtg	actgtgtgtg
35	tctgtgtgag	gccgtgtaaa	tgctactgta	tgtgtgatgg	tgacgtgtg	tgctgtgagt
	ttctgtctct	gcctggaggg	atagaggggtg	caggggtagc	tatctctggg	agatgggtgc
	cagggtgactg	acttgacgtg	tgtgcctgtg	tgacagaagag	tatgtggcag	tctgaacatc
	tgtgcacaca	cggcatctgt	gcgtggcact	gagacactgt	ggatgagggt	gtgcgatccc
	gctaggctgc	ccgggagcgt	gtgtacctgg	agacagagct	gtatgttagc	tgcaactgtg
40	gaggcaacat	gggctgtctc	gcagaactgc	gtgcgtgctt	ggctgttact	gctgttgtgc
	gcgtggttct	tggggtgagt	tcgtgaaatg	tgggtgtgcc	agggccatca	gcaagggtaa
	gaaccaggcc	gggcgcgggtg	gctcacgcct	gtaatcccag	ccctttggga	ggccgaggca
	ggcggatcac	ctgaggtcgg	gagatcgagg	ccagcctgac	caacatggag	aaccccgctc
	ctactaaaaa	tacaaaaaat	tagctgggtg	ggtggcgctg	gcctgtaatc	ccagctactc
45	gggagactgg	ggcagaaaaa	tcgcttgaa	ccgggaggtg	gaggttgctg	tgagccgaga
	tcgcgccatt	gcactccagc	ctgggcaaca	agagcgaaac	tccgtctcga	aagaaaaaaa
	gaaaaaaaaa	agggtaaaga	ccagtgaatg	ggcacgggag	gactgatgat	ggagtggggc
	atgcatgtag	tctgtaggtc	tgtgtgtgtg	aggaggagat	tgacaggatt	gagaaggcat
	gttttcatct	gagaattcag	aaacctaggc	ctgctcttcc	cctccatgtg	gccccctaag
50	ctgagccctt	ctttcctggg	cctgctttcg	gaacctagc	tccgcccag	agctctgacc
	ccacctcctt	tcctcaacca	cgcccttagg	ccagactcta	gtggaccccg	cctaaggcca
	cacccctttg	ggccaggctc	caccccttag	tctgtgggta	ccttctagaa	cccccttaa
	agtcagagct	tttttttttt	tttttttttt	gacagtcttg	ctctctctcc	caggctggag
	tgcatggcgg	tgatctcggc	tcactgcaac	ctctgcctcc	caggttcaag	tgattctcgt
55	gcctccacct	cctgagtagc	tgggattaca	ggtgocgcgc	accacgcctg	gctaattttt
	gtgtcttttag	tagagacagg	gtttcacctt	gttggccagg	ctggtctcaa	actcccaacc
	tcagggtgatc	cgccacacct	ggcctcccag	agtgtggggg	ttacaggcgt	gagccaccgc
	cccagccca	aagtcagagc	tctttatagg	agaactctaac	atgtaaccct	gaccctggcc
	ctaactaagt	caattccaaa	ccccttctcg	cctccagccc	tgacccact	cactgaggcc

	tgacccccact	tcttgagacc	agttccatcc	ctaaagccct	ggtctccctc	ccatccccag
	gctccagccc	ccacagcttt	ggcactaccc	ctgagcttgt	ccaggaatcc	tgtacccaat
	tttaccctca	catgtagttc	tagccaatcc	caggaatctg	tgaggtccag	ttagagtcca
5	gtaaccctac	ctgagcctgg	gctctgtcct	tgagcttgag	cctgggcttg	agaggtgcca
	ctcttattct	ccaggccctg	cccttgcccc	ctcagcatgt	cagacacca	ccctctagct
	ggtctggcct	cttgagtctg	aaacccaccc	ccagcccaag	ccccgcctct	gagccccgcc
	caacccattt	tccgttccca	gagcatgttc	tcgccaacaa	tgatgtttcc	tgtgaccacc
	cctctaacac	cgtgccctct	gggagcaacc	aggacctggg	agctggggcc	ggggaagacg
	cccggctcga	tgacagcagc	agccgcacat	tcaatggatc	cgactgcgat	atgcacaccc
10	agccgtggca	ggccgcgctg	ttgctaaggg	ccaaccagct	ctactgcggg	gcggtgtttg
	tgcatccaca	gtggctgctc	acggccgccc	actgcaggaa	gaagtgcagt	ggagtcccaa
	gaggaggggt	ggtggggacg	gggaagtggg	ggtgggggtg	gggaagtggg	ggtgggggtg
	tcattggaggt	gagggctggt	ggggacgggg	aagtgggggt	gggggtgtca	tggaaagtga
	gggttggttg	ggatgggttg	gggatgtggg	agcaggagga	ggtcgcagttg	gggataggac
15	taaggatgga	gttttgcggg	ggagcaaggt	gggaggatga	ggttgagagag	gggagagtgt
	tgtggtaggg	aatgggaagg	agccaaggat	gggttggtat	tggggttagg	agcatatatt
	tgttgaatgg	tttgggatgg	aggtggaatt	gggattggct	ttagaattgg	gggtgggtga
	aaatcgggct	gggggtgaaa	tgaagatagc	atggagatag	ggttgagatt	gggagcagat
	atagaatgaa	ggatggggat	tggagttttg	ggtgggggtt	gagatgggtg	gatttgggct
20	tgagaatgca	tatggtgatg	gcttctgggt	agggaaagaa	ttagggttgg	gaatgggatg
	ggttttgaat	tgtgactggg	atggggacag	gcatgggatt	ggagaccaag	agggagttga
	ggatggtttg	gggaccgggg	gtggggatgg	gggtggggct	ggggctgggt	gtgggggttg
	gattggcggt	ggacgtggag	atagagatca	gggttggttg	tgacctgccc	catcttctct
	agagttttca	gagtccgtct	cggccactac	tccctgtcac	cagtttatga	atctgggcag
25	cagatgttcc	aggggttcaa	atccatcccc	caccctggct	actcccaccc	tggccactct
	aacgacctca	tgctcatcaa	actgaacaga	agaattcgtc	ccactaaaga	tgtcagaccc
	atcaacgtct	cctctcattg	tccctctgct	gggacaaaag	gcttggtgtc	tggctggggg
	acaaccaaga	gcccccaagg	tgagtgtcca	ggttcttctt	gataccgacc	catctctgcc
	gccttccatc	tttctccact	tctcatttag	ttcctgtttg	acagtgcact	tccctaagggt
30	cctccagtgc	ttgaatatca	gctgtgctaag	tcagaaaagg	tcgcaggatg	cttaccgcag
	acagatagat	gacaccatgt	tctgcgcggg	tgacaaagca	ggtagagact	cctgccagggt
	gaggacacct	ctctttattc	agcagatata	cactgagtgc	caactcggta	acatggagcg
	ttgccaaatt	ctgagaatcc	agcaattgcc	aagacagtca	ggacccctgt	tctcacagag
	ctcataccct	agagtagtgg	tgttttagtag	aaataatgct	gagctgctta	tgtcatttcc
35	agtttttttag	tagccacatt	aaaacaggta	aaaaaggctg	ggcgagtggt	ctcacacctg
	taatcccagc	actttgggag	gctgaggcag	gcagatcacc	tttggtcagg	agtttgagac
	tagcctggcc	aacatggcga	aactctgtct	ctaaaaaaa	atacaaaaat	tagcctggca
	tggtggcggg	cgcctgtaat	ctcagctgct	caggaggccg	agacacaaga	atcacttaaa
	cccaggagggt	ggaggttgca	gtgagctgag	atcgtgccac	tcactccaac	ctgggagaca
40	gagtgcacct	tttgtctcaa	aaagaaaaaa	aaaaacaagt	aaaaaagaaa	caggtgaagt
	taactttaat	aaccaatgt	atcccaata	caatcatttc	aaagtgtaat	taataataaa
	caattatgaa	tgagatactt	tacattcttt	tcttgttttc	atattaagtg	tttgaaagtg
	agtatatatg	ttatgctgac	agcacatctc	aatttggact	agctacattt	caggtgctca
	gtagccacat	gtggctagca	gttactgtat	tggtggcac	ggatctagag	ggaaagatca
45	gggctgtttt	gtatggttgg	gcaggttgtg	cactgcataa	agataccata	tctaataagg
	gcactccgtg	ttacagatgt	cagttttggc	agttttcagg	cgtgtggtag	ttaagtgtct
	tgtttcaaca	aaatctgtaa	tatgacagtt	ttctagcaag	tgctggtaaa	atatcttgag
	gaagggaaaag	agaaatctgg	taggtatttt	tacaagagaa	tatttaatac	aggggattaa
	ttgcaaagct	gctggaaggg	ctggagggaac	aaagttaaaa	aataaaaaaac	tctgtgggtca
50	agaatctgca	taaatagggc	aatttcagag	agtggtaaag	gttaacccca	aaataaaaca
	tggttttttag	atagtaaaca	ataagggccca	atattcaaaa	aggtggtcag	gggagcctcc
	ttggagagggt	ggcatttgag	cagagaatgg	atgacacaaa	gaagctaaac	tctgtgaagt
	taaggggaaa	gaaaaggcac	gtgcaaaggc	cctgaggcag	taaggaaatt	ggctgattca
	aagaagaaga	gaaaaccaat	gcaactggag	aacaaaagtg	ggggcaacag	tgaaaagtga
55	cgctggagggt	gtaggcaggg	gcgaatgctc	tgcaagtatt	tcttgggtcac	caacacagag
	cttccctatg	ttctaattgga	agctgtatct	gttgaggaag	acagaattta	aaatcaaaact
	gttacatcaa	ccagcaccct	tctctgtatt	caggctccca	agggatctag	aaggacgtaa
	gttaacaagc	tctcattagc	aggggtgtgt	tttcaacagt	agttaggaag	ctggggattc
	aggagtactc	cagtcccatg	gctatgaaaa	gctcccccca	aattgtacaa	acctgacaaa

	tgcaacacct	ccccagctct	ccccatttct	tctctgtgcc	ctgggtgtgg	gggggtgggt
	tgcgaggggg	aaaactttta	acagaagaaa	gcacatctcg	gccgggctg	gtggctcaca
	cctgtaatcc	caacactttg	ggaggccgag	gcgggtggat	cactaggtca	ggagatggag
5	accatcctgg	ctgacacggt	gaaacccgtg	ctctactaaa	aacacaaaaa	attagccggg
	cgtgggtggca	ggcgccctgta	gtcccagcta	ctcgggaggg	tgaggcagga	gaatggcctg
	aacccggggag	gcggaacttg	cagtgagccg	aggttgcacc	actgcactcc	agcctgggca
	acacagtgag	actccgtctc	aaaaaaaaaa	aaagaaaaga	aaagaaatca	catctcattc
	aagtgggtggc	atttaaaact	atthagcctt	tctgtaggca	aggttagtat	cttgtttttc
	cagacctcaa	ggtgtttttt	tgtttgtttt	ttcataccgg	tgtgtggtct	gggtgtggcc
10	actaaaagct	acaagcaaga	aataataaca	actacaacaa	tactaatacc	aatagtataa
	aaataatagc	atctggctaa	ttgctggaca	ctgttttaag	tggtttgcac	gcctcagctc
	attaactcat	ttacctgtta	ttattggccc	tattttacaa	acaaggagcc	aaggctcaga
	gcagttaact	aacagcctct	caaaagaaac	tctgcagaga	tattaaattt	aaaaaataat
	gagagaaaatt	aaaccacaag	aaagttgaaa	tttagaggta	caggcagcta	agcttgtttg
15	ctttgaaaca	gtgtctgcta	ctgggaaaaa	ggcaagtctt	ggctttccta	ataattgata
	ccaggactct	gtaattcata	ttttgcatgc	atgtaagtaa	gaaatgaagc	cgggtgcaat
	ggcacatgcc	agtaatccca	gcactctggg	agactgaagt	gggaagatca	cttgagctca
	ggagttcaag	accagcctgg	gcaactaaaa	attaaaaaaa	taaaaaatac	aattgttttt
	attttagtag	attttattca	taccacttac	atcattattg	tagtatgtac	atattttattt
20	cttttctttt	cttttctttt	cttttttgag	acggagtctc	gctctgtcac	ccaggctgga
	gtgcaatggc	accatatcag	ctcactgcag	catgcgcctc	ctgggttcaa	gcatttcttc
	cacctcagcc	tcccaagtag	ctgggataac	aggcaccac	caccatgcct	ggctattttt
	ttttttccgt	agagatgggg	ttccaccatg	ttggccaggc	tggctctgaa	ctctgacctc
	ccagtgatct	gcctgcctcg	gcctcccaaa	ttgctggtat	tacaggtgtg	agccaccgtg
25	cccaggtggg	agatagacat	ttctctctac	ctcaaacaga	ggtccactca	agctactttt
	cattttcttc	ataaatatta	gccgagtggc	tattttgcac	cagggaatgg	tccaggtgct
	gtggatatgg	catcaggcaa	aacagaccaa	aaacttccct	ccgcgtggac	ctcatgttcc
	ccaagtggaa	gacaggcaat	aaagagatag	ataaatatgt	agtaaattaa	aaaaaaaaaa
	aattagccgg	gtgtggtggc	ttgcacctgt	agttccagct	acttgggagg	ctgaggtggg
30	agaattgctt	gagcccaaac	gtttgaggct	gcggtaaagg	atgactgcac	tgtctcactc
	cagacagcag	cctgggtgac	aaagcaagac	gtttttgtca	gaaagaaaaa	aaaaagagac
	gaaggggagga	aggagagaga	aaggaaggaa	ggaaggagaa	agaaaggaa	gaaggagaaa
	gaaagggaag	aaggaaggag	aaagaaagga	agaaagagaa	agaaagaaaa	agaaagaaag
	aaagaagaaa	gaaaagagag	aggaagggaag	gaaagaagga	aaagagggaa	aaaaatgact
35	gttgaagagc	agttagtatt	attataggag	ggtaattata	gggaggtatg	gggaattgaa
	gacaggaaac	acaaattagt	ccaagcgaat	ggatttctat	tgggagtgat	tctgcccta
	gaagacactg	gcaataaccag	gagacatttt	tggttgtcac	aactatatgg	aggggcatta
	ctggcaacta	atggatagat	gccaagtgtg	ctgttcaaca	tgctatgatg	cacacggcag
	gcctccacaa	caaaccatta	tccagcttca	gatgcccaca	gtgcccagat	cgaggaaccc
40	tcattccagg	gctgagaacc	gtatttttgc	agaaggggag	tataaggatg	ggttggtgga
	gaatggggga	ggaagggtgtg	tgtccagtaa	gagaaataag	gcctgcacag	gctggagggg
	agagttagag	agaaagggag	gcggagagat	acacgatgag	ggagacaggc	tggaacagaa
	agtagagacg	aagattcgag	atgtggagag	gaagggtcac	agaccccccc	gaaatgatgt
	gtggacaaca	ggaatctgga	agaggaagat	ggagtggaga	gtgacaaatg	gggtctaaag
45	gttgaacttg	gaggccaggc	atggtggctc	acgcctgtaa	toccaacact	ttggaggctg
	agggtgggca	atcacttgag	gccaggagtt	cgagaccagc	ctggccaaca	tggtgaaacc
	ccgtctctac	aaaaaaaaata	caaaaaatta	gccgggtgtg	gtgatggaca	cctgtagtca
	cagctacttg	ggaggctgag	gcaggagaat	tgccttgaacc	cgggagatgg	aggctgcagt
	gagctgaggt	caggccactg	cgctccaacc	tgggcaacag	agtaagactc	catctcaaaa
50	aaaaaaaaagc	tggatttgga	gtgaaatatt	aataacattc	tccctctctc	tccttttgcc
	tgtgtctcca	tctctgtctt	tttctgcatt	tcttcatctc	tgtactttcc	atctctgtgt
	gtctgttccc	atctgcttct	ccatctatgg	gcatctcttg	gtctctcatg	tctccttctg
	cccacttttg	cacatctctg	ctctctcat	gccccctttt	ctctcctgca	gggtgattct
	gggggggcctg	tggctctgcaa	tggctcctg	cagggactcg	tgtcctgggg	agattaccct
55	tgtgcccggc	ccaacagacc	gggtgtctac	acgaacctct	goaagttcac	caagtggatc
	caggaaacca	tccaggccaa	ctcctgagtc	atcccaggac	tcagcacacc	ggcatcccca
	cctgotgcag	ggacagccct	gacactcctt	tcagaccctc	attccttccc	agagatgttg
	agaatgttca	tctctccagc	ccttgacccc	atgtctcctg	gactcagggt	ctgcttcccc
	cacattggggc	tgaccgtgtc	tctctagtgt	aacctgggga	acaattttcca	aaactgtcca

gggcgggggt tgcgtctcaa tctccctggg gcactttcat cctcaagctc agggcccatc
ccttctctgc agctctgacc caaathtagt ccagaaata aactgagaag

5 SEQ ID NO. 4

hk6 amino acid

10 MKKLMVVLISLIAAAWAEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFL
GKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWG
KTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMMLCAGDEKYGKDSQGDSSGGLVCGDHLRGLVSWGNI
PC GSKEKPGVYTNVCRYTNWIKTIQAK

SEQ ID NO. 5

15 KLK6 nucleic acid

CDS 147.. 881

gtcgacccac gcgtccgget ggctggctcg ctctctcctg gggacacaga ggtcggcagg
cagcacacag agggacctac gggcagctgt tccttccccc gactcaagaa tccccggagg
cccggaggcc tgcagcagga gcggccatga agaagctgat ggtggtgctg agtctgattg
20 ctgcagcctg ggcagaggag cagaataagt tgggtcatgg cggaccctgc gacaagacat
ctcaccccta ccaagctgcc ctctacacct cgggccactt gctctgtggt ggggtcctta
tccatccact gtgggtcctc acagctgccc actgcaaaaa accgaatctt cagggtcttc
tggggaagca taaccttcgg caaagggaga gttcccagga gcagagttct gttgtccggg
ctgtgatcca cctgactat gatgccgcca gccatgacca ggacatcatg ctggtgcgcc
25 tggcagcccc agccaaactc tctgaactca tccagccctt tcccctggag agggactgct
cagccaacac caccagctgc cacatcctgg gctggggcaa gacagcagat ggtgatttcc
ctgacaccat ccagtgtgca tacatccacc tgggtgtccc tgaggagtgt gagcatgcc
accctggcca gatcaaccag aacatgttgt gtgctgggga tgagaagtac ggaaggatt
cctgccaggg tgattctggg ggtccgctgg tatgtggaga ccacctccga ggccttgtgt
30 catggggtaa catccctgt ggatcaaagg agaagccagg agtctacacc aacgtctgca
gatacacgaa ctggatccaa aaaaccattc aggccaaagt accctgacat gtgacatcta
cctcccagacc taccacccca ctggctggtt ccagaacgtc tctcacctag acctgcctc
ccctcctctc ctgcccagct ctgaccctga tgcttaataa acgcagcgag gtgagggctc
tgattctccc tggttttacc ccagctccat ccttgcatca ctggggagga cgtgatgagt
35 gaggacttgg gtcctcggtc ttaccccccac cactaagaga atacaggaaaatcccttcta
ggcatctcct ctcccaacc ctccacacg tttgatttct tcctgcagaggccagccac
gtgtctggaa tcccagctcc gctgcttact gtcggtgtcc ccttgggatgtaccttctt
cactgcagat ttctcacctg taagatgaag ataaggatga tacagtctccataaggcagt
ggctgttgga aagatttaag gtttcacacc tatgacatac atggaatagcacctgggcca
40 ccattgcactc aataaagaat gaattttatt atgaaaaaaaa aaaaaaaaaa aaaaaaaaaa
agggcggccg c

SEQ ID NO. 6

KLK6 nucleic acid

45 mRNA join(2001..2185,3084..3135,3559..3606,4346..4502,
8122..8369,9791..9927,11805..12483)

CDS join (3567..3606,4346..4502,8122..8369,9791..9927, 11805..11957)

50 acacttaaaa aatcttctga cttaaaaaaa aaagtatggt gattggaaaa tgtaaatgtg
catgcgtgct tggcatcaca tttoattggc caggacttcc ctggatgcta aaggtcctca
aatgccaggc tggggggctg ggacttggtc ccaagggaga tggggaccca gggcacgtct
gtgagaggag gggcaaggtc agcacaaggc acaggaaggc ctctctgggg caagggatac
agagaacaga gggatcctgg tccaggtggg agaggtgcag ctctgagttg ggggtgaggg
55 tgtgggtaca gagaggaagg gacccccag agagaggagg cagagggata gggcctggtc
actgggttgt gcaacatcag acttgctgtc tgtgaagata gcacgtcctg agaagaagg

	gctgaggtca	gtggggacca	aatgtgagag	ggagcaccgg	gagagtatac	tgaataccga
	agtagtcttc	atccctggag	tgatgggggg	tgcacaatgc	aagatgacaa	ttagattcaa
	tgcaagacaa	agaaaaggg	tggctgggaa	cagtggctca	tgcctatggt	cccagctcct
5	gggaagactg	aggcgggagg	gtcgcttgag	cccaggagg	ttgaggctgc	cacgagcaag
	gatcgtgcc	ctgcactcca	gcctaggcga	cagaacaaga	ccttgctc	aaagaaaaaa
	gaactttttt	ttttaagtta	cctgtagtgc	ccagcccaag	caggtgctga	gccagacttc
	attcctatca	ttgtccttat	tacgcagtga	cttccccctc	ctcattttctc	tccactctgc
	cacgcacaca	ccctcaccc	ccagcccata	ccaaccaccc	caaccactgc	ctgtggtttc
	ccatgtgcac	ccaggccagg	catttttcacg	gccttttcctc	ctgacctacg	cctggctcag
10	ctttctaggg	ccaagtcca	agacacctcc	ctaaatcttc	ccagatccct	ctgctactgc
	ccagcaccac	catcttatca	cagccccacg	tcgttcccaa	gtgctctccg	atttctgctt
	aaactccatgc	ctctcgctgt	gtgtccgc	ctcatcaata	agtccctcaag	tcctcttcca
	tcctgctagc	ttcctcatcg	ctcggaatc	atccccgcta	cttctggggg	aaactgactc
	ccttctgggc	acacacagtg	ctacccccgg	ggaaatctaa	gaagagaccc	aggagaagat
15	aagcacggag	agtcagagaa	tcaaggggaa	agaaagggag	agaggccggg	cacagtggct
	cacacctgta	atccagcact	ttgggaggcc	aaggtgggtg	gatcacctga	ggtcaggagt
	ttgagaccag	cctggccaac	atggtgaaac	ctcttcccta	ctaaaaatac	aaaaaacatt
	tagccggggc	tggtggtggg	tgctgtaat	cccagctact	tggaagctg	aggcaggaga
	actgcttgaa	ctcaggaggc	ggaggttgca	gtgaactgag	atcacaccac	tgactccag
20	cctgagtgac	agagcaagac	tccgtcaaaa	aaaaagaaag	aaagaaagaa	aagaagggaag
	gaaagaaaga	aggaaggaag	gaagggagga	aggagagag	gaagggagag	agggaaggag
	agagagaaaa	aaagagggag	agagacacaa	atacagagac	tgagatggga	gagagagaga
	gatggaagct	ccctcccctc	catggccagg	gagacagatg	gagcaagaga	cctcaggggt
	gggcagactt	ggaggagaag	gaccaggagg	atgtggagt	ccgaaatctc	cagtcagggg
25	caggtgggca	gtcagagact	gcaaaggagg	actgtcagac	agggacaaaa	ggaagccatt
	gatgtaaccg	ccctcccgc	tgcccgccgg	aagagaggtt	gaggccggag	ctgctgggag
	catggcactg	gggtgctggg	aggcggacaa	agcccgattg	ttcctggggc	ctttcccctat
	cgcgcctggg	cctgctccc	agcccggggg	agggcgggg	gccagtgtgg	tgacacacgc
	tgtagctgtc	tcccggctg	ctggctcgc	tctctcctgg	ggacacagag	gtcggcaggc
30	agcacacaga	gggacctacg	ggcagggtgtg	tgagtcaccc	caaccgcact	gaacctgggc
	aggctgcttc	ccagtgcggg	agggctctag	agcccggagt	gagggcctgc	aggctccctgg
	gtggcacaga	gagtgtctggg	ggtgcaggga	ggcctggggc	accatctgct	tgcccagag
	gccggaaattt	gtcttcagac	actttctttc	tccaaaaccc	ggaggtctaa	ggactgagcc
	gactagaact	tctctctgct	cagattcagg	ccccagcccc	tcttccctca	gacctaggag
35	tttaggtcct	agccctcct	ccctcagacc	caggagtcca	agttcccacc	tcttccctca
	gactcaggag	tccaggcccc	cagccccctc	tccctcagac	ccaggagtcc	aagttctcac
	ctcctcccctc	agaccagga	gtccaggccc	caagcccctc	ctccctcaga	cgcaagggtc
	caggccccca	gcccctcctc	cctcagactc	aggagtccag	gcccccaagc	ccctcctccc
	tcagacccag	gagtccaggc	cctcactgca	ctcagggaac	agtgtccct	tccctggagg
40	cctggtcagg	ggtcaccaag	agcagagcgt	ggggcgggga	ggaatgtgtg	tgggaggcct
	gggtaaggag	gaaaagggg	tagccagctt	cctggctcag	ggacctgaga	gacaggggtt
	aaaaggacgt	tccagaagca	tctggggaca	gaaccagcct	cttccaggga	ggcctgggag
	ctgggggtgt	gtgtctggca	gtccctgcag	ccctgggctc	tgcgggccct	gcgtcctccg
	cttggctctg	ccactgcac	tgagtgtctt	ctctcctcac	ggctcccgc	atttcttaact
45	ctttctgcct	cctcgtctca	aagctgttcc	ttcccccgac	tcaagaatcc	ccggaggccc
	ggaggcctgc	agcagggtgag	atcacagaca	tcacagaacc	tgccgggtgg	gcggggtggg
	tggccatttg	gcacagagcc	aggctccgag	gaaaactccc	atacagagga	agaacgtag
	ggccccctat	ggtaaccctc	tcctgtcgac	aggaaggcaa	atcagtgccc	aagaaagtag
	aaagatctaa	tcagaatctc	accatgggtt	actggaccag	tggaagtagt	tgaattctct
50	ttggcactgt	tttcgtggat	cctcttggaa	gatgtgggct	gaggaagaat	aatcaggag
	gctagatggg	aaggacagag	gtcaaggcag	gagaccatag	caggccagga	aggaaggaga
	ggatgcagag	ggagcagaca	gagggatggg	gggagggctg	aggcagtgc	taatggacca
	tgtggcttcc	cctctcagga	gcggccatga	agaagctgat	ggtggtgctg	agtctgattg
	ctgcagggtg	ggaaagggca	tttggatggg	gagggcttgc	agacagggtt	gggcttgttg
55	atggagaaga	ggctggtatt	ggggatgggg	atatgcacag	ggttgggggtg	ggggagcttt
	gaaatgagga	agacgttggg	gattaggcta	aggtggggga	atacagatag	ggaggggtgg
	gggaggtggg	tttgaagata	tgaggttttg	gggtgggggt	ggctttaggg	atggggatct
	aaacatagaa	gaggtaggag	gtaggttgga	aagttggaga	gagcccgga	ataggggata
	cagttggggt	tgtaattggga	atggggtaa	tttgggagtg	gaaatacaga	gaagcttttt

	ttttttgaga	caggggtctca	ctctgtcacc	caggctggag	tgtagtggca	tgatccatag
	ttcactgcag	acttgaactc	ttgggtctca	agtgaccctc	ccacctcagc	ctcccaagta
	gctgggacta	caggcgtatg	ccaccatacc	ctgctaattt	gtgtgtgtgt	gtgtgtgtgt
	gtgtgtgtgt	gtgtgtgtgg	agatgaggtc	tcactgtgtt	accgaggctg	gtctcaaaact
5	cctgggctca	agcgatcctc	ctgcctcagc	tgggattaca	ggcataagcc	actgcacctg
	accaatcttg	actggagtto	atggtgaggg	ggatgcgctt	ggtttctcca	gaactcctct
	ctgactcaga	tcttctctcc	ctcagcctgg	gcagaggagc	agaataagtt	ggtgcatggc
	ggaccctgcg	acaagacatc	tcacccctac	caagctgccc	tctacacctc	gggccacttg
	ctctgtgggtg	gggtccttat	ccatccactg	tgggtcctca	cagctgccc	ctgcaaaaaa
10	ccgtgagtct	acactgtaaa	tgaacagcag	atgcgactga	accctgaggg	tgtcttatag
	atgtcaggca	ggaggtgaca	taggcatooc	cccatcccca	gcacgagggc	atctgatagc
	caggtgcatt	cggctgttgc	ttaattgagt	acttaatgtg	tgccaggccc	tgcgggcata
	gcagtggaaa	agaaaataaa	aaaaagaaaa	caaaaaaaa	caagcaaaat	tgctgttttc
	ctgaacttac	tttctaattg	gggaattgga	tcatttgggg	acctgcaggg	cgtgatgggc
15	atgttgatgt	aattctgagc	acagtaggaa	gccactgggc	agttttgttt	ttgttgtttg
	tttgtttttt	gagacacagt	ctcgctctgt	caccagggct	ggagtgtagt	ggcatgatct
	cagctcactg	caacctctgc	ctcccagggt	ccagcgattc	tcctgcctca	gcaccocaa
	tagctgagat	tacaggtgtg	caccaccttg	cctggcta	ttttgtatgt	ttggtagaga
	cgggggtttca	ccatgttggc	caggtctggc	tcgaactcct	gacctcaggt	gatccgccc
20	cctcgccctc	ccaaagagct	gggattacag	gcatgagcca	ccaccacacc	cagcctgatt
	tacattttta	caagcaccct	ggctaaccag	tggaacgtgg	tctgggcaag	agagagggag
	ggaggccac	gtgggggctg	ttgctttcat	cgggcacat	aggaggggtg	cttgaaccca
	ggcggtcgca	gtgggatgg	agggatgttg	aatatcttgg	gatgtggaat	tctgagactg
	agccagcaga	atctggcaac	gaggaacagg	agggagagga	agaagcacgg	ctggcttccg
25	tgtatttgtc	ctgaacaact	gggtgttttg	ccacgtcttt	ctctgagttg	tgggagaggg
	aaagagaaac	aggccgggtg	taggcagggg	agcatctgac	attttgcttt	agccacgatg
	agttggagat	gccggggaga	tgtcccagca	gggaggccag	ggaggactct	ggagctcaga
	ggagaggtca	gggctggagg	ttaaaatgaa	ggcatcgtca	gcaaacaggt	gtattttaaa
	ccatgggact	agatgagatc	atccaaaaag	ctggcatagt	tggaggagct	ggaggggcca
30	ggacaaaaac	cctgggcgct	gatcctcact	agtcagattc	acgacagctg	ccacttggtt
	gatgctaact	accaatcagg	tgtctgagtga	aaccatgtac	acacctttcc	tggaatgccc
	accacaaggg	actcttgga	ccatttttga	aatgaggaaa	ctgaggtgca	gggaaatagc
	aagtgacaat	ccctgggggtg	gttccccctga	ccccaggag	accttggtg	actctcacca
	ccatcattca	ttccttttgat	gtacattgac	taagagcacc	tgctaagtgc	cacattcgag
35	ttggggcagt	gagattcagc	aatggatggg	acacacacgt	catccctgcc	ctcgggagca
	caaggacaga	aagggtgcaga	caagcaaaagt	gagggtggg	catggtggtc	cacgcttgta
	atcccagcac	tttgggaggg	cgaggtgggt	ggattacctg	agttcgagac	cagcttggcc
	aacatggctc	aaccctgtct	ctactgaaaa	tacaaaaaat	tagccaggcg	tgggtggggg
	cttctgtaat	tccagcaact	tgggaggcta	aggcaggaga	attgcttgaa	cgtgggaggg
40	ggaggttgca	gtgagccgag	atcgcgccac	tgactccag	cctgaaccac	agagcgagac
	tctgtctaaa	aaaaaaaaaa	ggaaagaaag	aagcagcaaa	ttgggctggc	cgtgggtggc
	catgcctgta	atcccagcac	tttgggaggg	cgaggcgggt	ggatcactcg	agcccaggag
	tacaaagctg	cagtgagctg	tgatctacag	aacaccactg	cagatccagc	ctgggtgaca
	gagcgagacc	ctgtctcaaa	aaaacaaaca	aacaaaagaa	gcaaaccctt	caaaacccca
45	tataattaca	aattatgaag	gaaaagaata	cgggtaccta	ctttagatgg	aggaggggtc
	ggaaggactt	tctaattgaga	taaaatccaa	gaggaggcat	gaagatggga	aaaggaatgt
	tcagggcaga	ggaaaggctg	tgataacacc	cctgaggtga	gaaccgtctt	gagtattctc
	agaaaaataaa	atttcccgtt	cactgggggg	cagaaggtgc	tgggagataa	ggttggaaag
	tgactacagc	cagatcacac	aggggtccca	gtgccaaagt	gaggagccca	ggctttatct
50	ttaggacaat	ggggagccat	gggtgatgtc	tgagcaaggg	agtactctc	tgtttcagga
	atatgtatca	aacacctatc	ctgtgocagg	tgctgatcaa	cgcactggag	atactatata
	tgaatagaac	aaaaatcccc	atcttgacat	cctagagctg	cactgtctaa	tatggtagcc
	atcagccaca	tatagcaaat	tacattgaaa	ttaatgaaat	ggaaaatcca	caagccacat
	ttcaagtact	cagcagccac	ctgtagcttg	tggttcccc	agccacctct	ggcagctgca
55	gatcgagatc	atggcatcgt	agcatttagt	ggacagcatt	gctctgcaag	gaggagaaat
	aacacaatga	gtaaatatgt	aacaataaat	atatagcagg	toggatgatt	gtgatagggt
	ctctgggtgga	acagaaagca	ggggaggggg	ataggaattg	cctactaaca	ggtatttgta
	ttttaatttg	gcaactaagg	aaggcttccc	tgagaggcga	cattttaagg	aagtgagggg
	gtgagctatg	cagatacttg	gaggacagac	ttgctggcag	agggaacagc	agtgcacagg

	ccctgaggtg	ggaagatcac	tattgtgttc	aaggcaagac	aggggaagcca	gcgttttggt
	ggagcagagg	gagagaaggg	gagagtggga	ggagaagatg	tctgtgagat	gatggggcag
	tgcttgcaag	gcctggtgtg	ccacgttgag	aactttggct	ttgattctga	gtgagatggg
	agtcatagga	ggggctgagc	agaggaggca	caggaccaac	ttacattgtt	aaaatatctc
5	tggttgcttt	gtggaggatg	gactgtgggg	gaccagagac	agagcaggga	gcccagtgag
	gaggctactg	ctctagtcca	ggtaggaagt	gaaaaggcag	ctcaaaccac	gatggtagcc
	gtgggaaagg	tgagatgtgg	ccagattctg	gatatgcttc	agagaggcaa	aaggaattct
	ggacagcttg	gatgtagggc	atgaaataaa	gagagtgaag	aatagccccc	aagattatct
	tgaaaggatg	gaattgccat	ttacccagct	ggggaagact	gtgggaggag	caggccagcg
10	attcatgact	tcccagccct	ctctgaagcc	tcaactgcag	cccaagggct	ccaggtgaga
	cccagccctc	ttccttccca	ggaatcttca	ggtcttcctg	gggaagcata	accttcggca
	aagggagagt	tcccaggagc	agagttctgt	tgtccgggct	gtgatccacc	ctgactatga
	tgccgccagc	catgaccagg	acatcatgct	gttgccgctg	gcacgccccg	ccaaactctc
	tgaactcatc	cagcccccct	ccctggagag	ggactgctca	gccaacacca	ccagctgcca
15	catcctgggc	tggggcaaga	cagcagatgg	tcagtagtgg	gaggctgggtg	gggagcaggg
	tactggctac	ttgggggaagt	gtgcccgaag	atggggagtg	ggaaaatttg	tgagggggca
	tgggaagatg	ggctaattgg	gaggaccaat	gggacagggt	ttcaatggga	gaaaggtcaa
	gggggagggg	gagtgaattt	gggagctggg	ccagtgaagt	aacagccaat	ggaaaatgta
	gaccaatggg	tgaatagcat	gggagagatg	gaacataaga	tgaaggttca	ataaagaggg
20	aaggtcagtg	gggagatgct	aatcaggaag	gatgtcaaag	gtcaaagggg	actgatcagg
	attcattgaa	cagcaggaag	gaataatgga	gaaggaactg	atggaagaag	agaaaaccaat
	aaagcacaaa	agccaactga	aggatgtgaa	ttgagacagt	gaatgggggt	atagctgatg
	gaagagggac	taaggggaaa	ggatcaatgg	tccagaggag	tcactagagg	aaaaaacagg
	tccaatagat	cagcaggatc	catgaagggt	ggcctgtgtg	tgaagggcca	ataagaaagg
25	tgaaccattg	gatgaagggc	cagtgggaag	gcagagacaa	tgggggagga	tgccgcaagt
	tagaaaagga	ccaatgaggg	aggtggacca	ttggatgaag	ggctaataag	aagggagagc
	cagtggggga	tggtgaggcc	agttagaaaa	ggaccaagga	gggaagcaga	ccaataggaa
	gagagagcca	atgagggagg	gcagggccag	ttaggaaaag	accaatgagg	aaggtagacc
	attggaggaa	gggccaatag	aaagggagga	tccatgaggg	agggtgggga	cagttagaaa
30	aggaccaatg	atggagggtg	accattggat	gaagaaccaa	tagaaaaggaa	gaaccaatgg
	gagagggcat	ggccagttag	gaaaagacca	atggtcacag	agtgaaccaat	caagatgaat
	caatgggcag	gaagtgtcca	atgaagaatg	gactactgat	caggaggggt	acagtagagg
	agggcgtaac	agaggaagag	tcctccaggt	caactgaaac	tactgaagaa	ggtgggacca
	gtggaagaga	gaaaagtgga	ggagggacct	aagagaaaag	gaaaaccaat	aggaaatgag
35	gactcctgga	gaagagacta	ttaatgagga	agacagccaa	tgggggggaa	gaatgataga
	aagagggacc	aattaggagg	cagggacgat	ggtaatgaga	tgtaaagaatg	agagacaaac
	aggaagaggg	gtgccaatag	aaaagagggg	ccaatagagg	atggaggact	tatagggggt
	ggggggtgac	tggggaggat	gaggggagtg	caaggcctgg	gctgagttct	gcccattctc
	cccctaacag	gtgatttccc	tgacaccatc	cagtgtgcat	acatccacct	ggtgtcccgt
40	gaggagtgtg	agcatgccta	ccctggccag	atcaccacga	acatgttgtg	tgctggggat
	gagaagtacg	ggaaggattc	ctgccaggtg	aggtgaccgg	gatctgccac	ttacacagcc
	agggacagga	cgaagtcaca	aaaacatggc	cagacacagg	aagagagaga	ccacaggccaa
	aagagagctt	tacagagaca	gatagagaca	ggctgaggga	gaacccaagc	cttgaaaaga
	agagacttag	ttcaacacac	agagacacag	tcagggatat	gcagagatat	aaagacacag
45	ccagcagaga	caggaagtgc	agagacaagg	atggaggccg	cgggatcaag	aaccagagag
	gccaggagca	gcggctcatg	cctgtaatcc	cggcactttg	ggaggccgaa	gcagtaggat
	cacctagggt	caggagtctg	agaccagcct	gatcaacatg	gtgaaaacct	atctctacta
	aaaatacaaa	aattaggatg	ggcacagtgg	ctcatgcctg	taatcccagc	accttgggag
	gccgaagcag	gaggatcacc	tgggggtcagg	agttcgagac	cagcctgatc	aacatgggtg
50	aacctatctc	ctactaaaaa	tacaaaaatt	aggatgggca	cagtgggtca	tgccgtgtaat
	cccagcacct	tgggaggccg	aagcaggagg	atcacctggg	gtcaaagagat	tgagaaccagc
	ctggccgata	tgggtgaaacc	ctatctctac	taaaaaatata	aaaattagct	gggcctgggtg
	cagcgccctg	tagtcccagc	tactcaggag	gctgtggcag	gagaatcact	tgaacctgga
	ggcgagggtt	gttgacagtga	gtcgagatca	tgctactgca	ctccagcctg	gcaacagagc
55	aagattccgt	ctcaaaaaaa	aacaaaaaaa	caaaaattac	gcaagcatgg	tgggacacac
	ctgtagtccc	agctactogg	gagggctgagg	ctggagaatt	gcttaaacc	aggagggcaga
	ggctgcagtg	agctgagatc	acgccactgc	actccagcct	ggggacagag	ccagactctg
	tctaaaaaca	aaaagaacca	aagagaagta	gtaagggaagc	agatgggtgtg	aggggactgt

	ccttcctcaa	acagagcccc	cacgagtcct	gtcagaaaac	gaccaggctc	tggaggaggg
	agacactagc	tggggaaagg	ggactccctc	ccgaataactt	taacttgggt	ttcctccatt
	gtcatccatc	caggctctcc	tctttatgcc	agaatgacta	atgcactgag	ggatgtgcag
	agaccaacca	agggggagac	acaggcagaa	acggagacac	aggcagaaac	agggacagag
5	acagggaagg	cgatacatag	caagttggac	gcaaagaaaag	ggcaggtggg	cgagactgtc
	ctcaagacac	gaggtggaga	ggtgtccctg	gacagaatag	tgccaggcat	atctctccct
	gggcccctccc	tacctctccc	acctgggtct	tatcgtctcc	tcctccccct	cctccctctc
	ctcctcttcc	tcctcctcct	cctccctcat	catcttcttc	ttttctctct	ctctccatcg
	gtctctacac	ctctgcctct	ctccacacct	ctcagtctcc	attcttaaatt	tgtttctctt
10	tcttgctctc	tatgttccct	tgcattcttg	cattccctatc	tctgtgtctt	tgagtctcct
	ttattctctc	tctaccattc	tctctctgtg	cccttggtgtg	tcttactgtc	tctctctctg
	tctctctgtc	cctgagtctt	tctctccatc	tttcagtaag	tacctctgtc	cctttctacc
	tctctctctg	tcacacacac	acacacacac	acacacacac	acacacacac	acacacagtc
	tctgggtttc	tatctgtatc	tgactttctc	cctctttcct	gcagggtgat	tctgggggtc
15	cgctgggatg	tggagaccac	ctccgaggcc	ttgtgtcatg	gggtaacatc	ccctgtggat
	caaaggagaa	gccaggagtc	tacaccaacg	tctgcagata	cacgaactgg	atccaaaaaa
	ccattcaggc	caagtgacct	tgacatgtga	catctacctc	ccgacctacc	acccactggg
	ctggttccag	aacgtctctc	acctagacct	tgccctccct	cctctcctgc	ccagctctga
	ccctgatgct	taataaacgc	agcgacgtga	gggtcctgat	tctccctggg	tttaccctag
20	ctccatcctt	gcactactgg	ggaggacgtg	atgagtgagg	acttgggtcc	tcggtcttac
	ccccaccact	aagagaatac	aggaaaatcc	cttctaggca	tctcctctcc	ccaacccttc
	cacacgtttg	atttcttcct	gcagaggccc	agccacgtgt	ctggaatccc	agctccgctg
	cttactgtcg	gtgtccctt	gggatgtacc	tttcttccct	gcagatttct	ccactgtaag
	atgaagataa	ggatgataca	gtctccataa	ggcagtggtc	gttggaagaa	tttaagggtt
25	cacacctatg	acatacatgg	aatagcacct	gggccaccat	gcactcaata	aagaatgaat
	ttt					

30 SEQ ID NO. 7

KLK6 nucleic acid

CDS 246..980

35	aggcggacaa	agcccgatgtg	ttcctggggc	ctttcccat	cgcgctggg	cctgctcccc
	agccgggggc	agggcgggg	gccagtgtgg	tgacacacgc	tgtagctgtc	tccccggctg
	gctggctcgc	tctctcctgg	ggacacagag	gtcggcaggc	agcacacaga	gggacctacg
	ggcagctggt	ccttcccccg	actcaagaat	ccccgaggc	ccggaggcct	gcagcaggag
	cggccatgaa	gaagctgatg	gtggtgctga	gtctgattgc	tgacgcctgg	gcagaggagc
40	agaataagtt	ggtgcatggc	ggaccctgog	acaagacatc	tcacccctac	caagctgccc
	tctacacctc	gggccacttg	ctctgtgggtg	gggtccttat	ccatccactg	tgggtcctca
	cagctgcccc	ctgcaaaaaa	ccgaatcttc	aggtcttccct	ggggaagcat	aaccttcggc
	aaaggagag	ttcccaggag	cagagttctg	ttgtccgggc	tgtgatccac	cctgactatg
	atgccgccag	ccatgaccag	gacatcatgc	tgttgcgcct	ggcacgcca	gccaactct
45	ctgaactcat	ccagcccctt	cccctggaga	gggactgctc	agccaacacc	accagctgcc
	acatcctggg	ctggggcaag	acagcagatg	gtgatttccc	tgacaccatc	cagtgtgcac
	acatccacct	ggtgtcccgt	gaggagtgtg	agcatgccta	ccctggccag	atcaccaga
	acatgttgtg	tgtctgggat	gagaagtaog	ggaaggattc	ctgccagggt	gattctgggg
	gtccgctggg	atgtggagac	cacctccgag	gccttgtgtc	atggggtaac	atccccgtg
50	gatcaaagga	gaagccagga	gtctacacca	acgtctgcag	atacacgaac	tgatccaaa
	aaaccattca	ggccaagtga	ccctgacatg	tgacatctac	ctcccgacct	accaccccac
	tggctggttc	cagaacgtct	ctcacctaga	ccttgccctc	cctcctctcc	tgcccagctc
	tgaccctgat	gcttaataaa	cgacgcgacg	tgagggtcct	gattctccct	ggttttacc
	cagctccatc	cttgcacac	tggggaggac	gtgatgagt	aggacttggg	tcctcgggt
55	tacccccacc	actaagagaa	tacaggaaaa	tcccttctag	gcactctctc	tccccaaacc
	ttccacacgt	ttgatttctt	cctgcagagg	cccagccacg	tgtctggaat	cccagctccg
	ctgcttactg	tcggtgtccc	cttgggatgt	acctttcttc	actgcagatt	tctcacctgt

aagatgaaga taaggatgat acagtctcca tcaggcagtg gctgttggaa agattttaaga
 tttcacacct atgacatata tgggatagca cctgggccgc catgcactca ataaagaatg
 tatttt

5

SEQ ID NO. 8

Hk10 amino acid

MRAPHLHLSAASGARALAKLLPILMAQLWAAEAALLPQNDTRL
 10 PEAYGAPCARGSQPWQVSLFNLGSLFHCAGVLVDQSWVLTAHCGNKPLWARVGDHLL
 LLQGEQLRRTRTSVVHPKYHQSGPILPRRTDEHDLMLLKLARPVVPGPRVRALQLPY
 RCAQPGDQCQVAGWGTTAARRVKYNKGLTSSITILSPKECEVFYPGVVTNNMICAGL
 DRGQDPCQSDSGGPLVCDLTLQGILSWGVPYPCGSAQHPAVYTQICKYMSWINKVIRSN

15

SEQ ID NO. 9

KLK10 nucleic acid

Gene 1...1580

CDS 220...1050

20

catcctgccca cccctagcct tgctggggac gtgaaccctc tccccgcgcc tgggaagcct
 tcttggcacc gggacccgga gaatccccac ggaagccagt tccaaaaggg atgaaaaggg
 ggcgtttcgg gcaactgggag aagcctgtat tccagggcc cccagagc aggaatctgg
 25 gacccaggag tgccagcctc acccagcgag atcctggcca tgagagctcc gcacctccac
 ctctccgccc cctctggcgc cggggctctg gcgaagctgc tgccgctgct gatggcgcaa
 ctctgggccc cagaggcggc gctgctcccc caaaacgaca cgcgcttggga cccgaagcc
 tatggctccc cgtgcgcgcg cggtcgcag ccctggcagg tctcgtctct caacggcctc
 tcgtccact gcgcgggtgt cctgggtggac cagagttggg tgctgacggc cgcgactgc
 30 ggaaacaagc cactgtgggc togagtaggg gatgaccacc tgctgcttct tcagggagag
 cagctccgcc ggaccactcg ctctgttgtc catcccaagt accaccaggg ctacggcccc
 atcctgccaa ggcgaacgga tgagcacgat ctcatgttgc tgaagctggc caggcccgta
 gtgctggggc cccgcgtccg ggccttcag cttccctacc gctgtgctca gccgggagac
 cagtgcacag ttgctggctg gggcaccacg gccgccgga gagtgaagta caacaagggc
 35 ctgacctgct ccagcatcac tatcctgagc cctaaagagt gtgaggtctt ctaccctggc
 gtggtcacca acaacatgat atgtgctgga ctggaccggg gccaggacct ttgccagagt
 gactctggag gccccctggt ctgtgacgag accctccaag gcatcctctc gtgggggtgt
 taccctgtg gctctgccc gcatccagct gtctacaccc agatctgcaa atacatgtcc
 tggatcaata aagtcatacg ctccaactga tccagatgct acgctccagc tgatccagat
 40 gttatgctcc tgctgatcca gatgccaga ggctccatcg tccatcctct toctcccag
 tcggctgaac tctccccttg tctgcactgt tcaaacctct gccgccctcc acacctctaa
 acatctcccc tctaacctca ttccccacc tatccccatt ctctgcctgt actgaagctg
 aaatgcagga agtgggtggca aaggtttatt ccagagaagc caggaagccg gtcacaccc
 agcctctgag agcagttact ggggtcacc aacctgactt cctctgccac tccctgctgt
 45 gtgactttgg gcaagccaag tgccctctct gaacctcagt ttctcatct gcaaaatggg
 aacaatgacg tgcctacctc ttagacatgt tgtgaggaga ctatgatata acatgtgtat
 gtaaactctc atggtgattg tcatgtaagg cttaacacag tgggtggtga gttctgacta
 aaggttacct gttgtogtga

50

SEQ ID NO. 10

KLK10 nucleic acid

Gene 1..5574

mRNA join(48..120,605..701,2455..2635,3589..3863,4195..4328, 4793..5474)

55

CDS join(614..701,2455..2635,3589..3863,4195..4328,4793..4945)

Promoter 1...47
 5'UTR join(48..120,605..613)
 exon 48...120
 exon 605...701

5	ttgggggtcaa	aaggggaaggt	cccgccaggg	gtccctgggc	agaggatacc	agcggcagac
	cacaggcagg	gcagaggcac	gtctgggtcc	cctccctcct	tcctatcggc	gactcccagg
	tgaagctacc	tgcaccccac	ccgggttggg	gtggattgcg	agaggatggg	tgggaacccc
	cgggccacag	gcaggagccg	gcttagagcc	tcggtttctc	cactgcggga	cgcggaagtc
10	ccccgcgtgt	gaggttgaga	aagaggctcc	cactggctcc	gagcctcgga	tccccacccc
	gcgcgtgaag	gaggggaaa	cctcgggcgc	ggcgtggctg	cagccagggt	agctggggcg
	cgagagcgcg	tccactcggg	cacagggagg	acgggaagat	gccgcgagg	gcgtcattag
	ggtaattgtg	cccattaccg	tgttccagcc	cgaatctccc	gtctgccagc	ccctgggggt
	atcggctgca	ggtcaaaaag	gtgcttgccg	gctgggggtg	cccaggctgg	gcggatgagc
15	gcggcgagg	gggggtctct	aacggagcat	ctgttttaac	ccgcccctgc	acacaccccc
	gcagatcctg	gccatgagag	ctccgcacct	ccacctctcc	gccgcctctg	gcgcccgggc
	tctggcgaag	ctgctgcgcg	tgtgatggc	gcaactctgg	ggtaagggtg	gggacagggg
	gcggggagag	gcgcgggtgg	gaggcacggg	cgggagggca	atgtgttccc	gtcaccaagc
	cccgcgaccc	tctcctcccc	cgagaccccc	gcacccaccc	agcgtctccg	agcacggccc
20	gcccccaagt	cagctggggc	cttctctctg	ctcggcccct	gggtgaccog	ccccactcag
	gcctgtcccg	atttctgcca	cccggatcct	cgctcttccg	tggactcttc	ggcgtgttct
	ttctctcctt	cttacgccgc	cccatcccg	ccccgctcca	ttttacacta	ccgtgttttg
	ttttgtttgt	ttgtttgttt	gagacggagt	ctcgtctctg	cgcccagggt	ggagtgcagt
	ggcgcatctt	cggctcactg	caagctccgc	ctcccgggtt	cacaccattc	tcctgcctca
25	gcctcccag	tagctgggac	tacaggcgcc	cgccaccaag	cccggctagt	tttttgtatt
	tttagtagag	atgggatttc	accgtgggtc	cgatctcctg	gcctcgtgat	ccgcctgcct
	cggcctccca	aagtgcctgg	attacaagcg	tgagccaccg	ctcccggcca	caccacagtg
	ttttatcctg	agtcttgcc	taccgctttt	tgccctctcc	cctcactttt	ttttctctcc
	tttccctttc	tctctctttt	ttctttttct	ttctttctct	tctttctttt	gttcttcttt
30	tccttctctc	ctttccttcc	ttcctttcgt	ttgtttcttc	tttcttgttt	tactttctct
	cttatttttt	cttcttttct	tcttgttttt	tttctttctc	tctctttttc	tttcttctct
	tttttttttt	tttttttgag	acagggcagt	gctctgtctc	cgtggctgga	gtacagtggc
	ccaatcagag	ctcactgcag	cctcgacctc	ctgggctcaa	gcgatactca	gcctccagag
	tagctggtac	cacaggcatg	caccaccaca	tcgggctttt	tttttttttt	tttttttttt
35	tttttttgag	acagggctc	actctgtcgc	ccagactgga	gtgcagtggc	ccaatctcgg
	ctcattgcaa	cctccacctc	ctgggctcaa	gcgatoctcc	cacctcagcc	tcccaggtag
	ctgtgactac	aggcgcatgc	ctccgcgact	acttttttgt	tgttgttgtt	gtttgttgtt
	ttttgtagag	actgggtctt	gctgtgttgc	ccgggctggg	cttgaattcc	cgagctcaag
	cggtccaacc	gcctcggctt	cccaaagtgc	tgggattaca	ggcgtaaaac	actgcgcccc
40	accctctctc	tggttttcaa	tcccggtttt	ttattcacac	cccttctctc	ccccgatccc
	cgagttctat	ccccgcaccc	ttacctcccc	gccgcgttca	atccccgccc	ctctatogac
	cagcgacgtt	ctagccagct	ctocaggcgc	gctgcgttca	gtccctgccc	tccagaccca
	ccctattctg	tctcattact	ccacgctacc	ctatcccagc	ttccttccac	tttcacgcgc
	ttcttctcct	cccattcctt	cgggtgcacg	gaaaccccca	atatttccct	accacccctg
45	cgttctgggt	gcgtccccc	tccccgaacg	cagtccagtg	ccacagccca	gctccaaccc
	caaaccacaga	ccctgccctc	cgtgctttga	ttccgtcccc	tttctttctc	ccagccgcag
	aggcggcgct	gctcccccaa	aacgacacgc	gcttgacc	cgaagcctat	ggcgccccgt
	gcgcgcgcgc	ctcgcagccc	tggcaggctc	cgctcttcaa	cggcctctcg	ttccactgog
	cggtgtcctt	ggtggaccag	agttgggtgc	tgacggccgc	gcactgcgga	aacaagtagg
50	aggagatcca	tccccgagga	cgccacgggg	ggctgtggag	gcggcctcca	gggaggagcg
	ggcagggcgg	ggtctctcgg	aactcccaca	gctggagggt	cgtccccggg	tgtccttcca
	gcaggaggag	agaccgggct	tgcgctgtgg	ccgccagggg	acgggtgtgg	ccttttccgc
	atcttctggc	ccgtcactcc	tctcccgtct	attctccttg	agctctagga	ggagggtgggt
	ccctgcaacg	gatagaagcc	agggtcgggt	gtggtcagga	atttagaact	aaaggaaaag
55	gttcacttcc	tgagtccccg	ttgaaggagg	aagggttggg	tattaccaca	gagaaaaatgt
	ggagtgtggc	tgggctcggg	ggctcacgcc	tgtaatccca	gcactttggg	aggccaaggc
	gggtggatca	cctgagggtca	ggagtccaag	accagcctgg	ccaacatggg	gaaaccactt
	ctcaactaaa	aataaaaataa	aataaaaaaat	aaaaaatttt	aaaaaaatta	aaaaaaaaaa
	aaggctgggt	gtgggtggcgg	gtgctgttaa	tcccagctac	tcaggaagga	ggctgaggca

ggagaactgc ttgaacctgg gaggtggagg ttgcagtgag ccgagattgc gccattgcat
 tctagcctgg gtgacaagag cgaaactctg tttcaacaaa gaaaagaaaa agagaaaaga
 aaatgtggaa ggcttaccta ggtgtccagg cccccagccc tcctcaattc ctgcagatcc
 tcagagctca aacaactgat tcctcctccc catgtccact gaggtccctt tctcccacaa
 5 ggccctcttc cctcagactc ttcttatctc caggccctgc ttactgccc acctgctttc
 ccagtccttg tgaagggttt gccttcacat gcctcttcct tccccaggc cactgtgggc
 tcgagtaggg gatgaccacc tgcctcttct tcagggcgag cagctccgcc ggacgactcg
 ctctgttgct catcccaagt accaccaggg ctccagcccc atcctgccaa ggcgaacgga
 tgagcacgat ctcatgttgc taaagctggc caggcccgtg gtgccggggc cccgcgtccg
 10 ggccctgcag ctccctacc gctgtgctca gcccggagac cagtgccagg ttgctggctg
 gggcaccacg gccgcccgga gaggcaagag ctggggctct gaggccagaa cctcaggagg
 agggggctga gggcctgaac cctgggtct cagggaaggat gggctgggga ctggattcct
 ggatctgagg gaggacgggc tggggctcta gatgcctggg tctgtgagtc tgaggggagg
 aggggctggg ggcctggact cctgggtcta agtggggagg ggctggggcc aggtattcttg
 15 agtctgaagg aggaggggct ggggcttagg atagaaacgg tcttgtatct ggactcctgg
 ctccccaaag attgggggct ggaccacagg attactggca tattctccct tcagtgaagt
 acaacaaggg cctgacctgc tccagcatca ctatcctgag ccctaaagag tgtgaggtct
 tctaccctgg cgtggctacc aacaacatga tatgtgctgg actggaccgg gccaggacc
 cttgccagggt agggctctgaa caggagagat ctctgactcc tgggagggag gacagggagg
 20 ttatgggaaa agagcagacc ctgtgccgga tccaaactc cattcccaa cccatccttg
 accccaactc ttaccagac ctaaccccct cctcatccct atcctcaatc ccatttccat
 cctaacccca ccccatctcc atctccaagc ccattttcat cccctcacct tccatgaact
 acaatcccaa cccaagtctc actgtgcctt cattctcatc cccagccca acctccata
 acctgaagtc cacctccatt cctaccttc agctcatacc taattccaac cccatcccat
 25 cctcgtcttt atcccaaccc aaccccttcc ttccccacca ctgccccaga tcccaaagtg
 acagctctca cgttggcaca tttatttgat ctctccttcc tgccaccccc agagtgactc
 tggaggcccc ctggtctgtg acgagaccct ccaaggcatc ctctcgtggg gtgtttacc
 ctgtggctct gccagcatc cagctgtcta caccagatc tgcaaataca tgtcctggat
 caataaagtc atacgtcca actgatccag atgctacgct ccagctgatc cagatgttat
 30 gctcctgctg atccagatgc ccagaggctc catcgtccat cctcttctc cccagtcggc
 tgaactctcc ccttgtctgc actgttcaaa cctctgccgc cctccacacc tctaaacatc
 tcccctctca cctcattccc ccacctatcc ccattctctg cctgtactga agctgaaatg
 caggaaagtg tggcaaagggt ttattccaga gaagccagga agccggtcat ccccagcct
 ctgagagcag ttaactgggt caccacaact gacttcctct gccactcccc gctgtgtgac
 35 ttggggcaag ccaagtgcct tctctgaacc tcagtttcct catctgcaa atgggaacaa
 tgacgtgcct acctcttaga catgttgtag ggagactatg atataacatg tgtatgtaaa
 tcttcatgtg attgtcatgt aaggcttaac acagtgggtg gtgagttctg actaaagggt
 acctgttgct gtgatctgac cactcccg tgaagcgtg tgtccaggga agaagtgcac
 40 agggtagccc ccaatcccaa ccttccatcc ccaaccctta gggatgatgg aaga

SEQ ID NO. 11

Hk11 amino acid

45 MQRRLRWLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA
 TGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIV
 HLGQHNQLKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPV SITWAVRP
 LTLSSRCV TAGTSC LISGWGSTSSPQLRLPHTLR CANIT IIEHQK CENAYPGNITDTM
 50 VCASVQEGGKDSCQGDSSGGLVCNQLSGIISWGQDPCAITRKP G VYTKVCKYVDW IQ ETMKNN

SEQ ID NO. 12

Hk11 amino acid

MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTR
 55 LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNQLKEEGCEQTRTATESFPHPGFNNSL
 PNKDHRNDIMLVKMASPV SITWAVRPLTLSSRCV TAGTSC LISGWGSTSSPQLRLPHT

LRCANITIIIEHQKCNAYPGNITDTMVCASVQEGGKDSQGDSSGGPLVCNQSLQGIIS
WGQDPCAITRKPGVYTKVCKYVDWIQETMKNN

5 SEQ ID NO. 13

KLK11 nucleic acid

	aggaatctgc	gctcgggttc	cgcagatgca	gaggttgagg	tggctgcggg	actggaagtc	61
	atcgggcaga	ggtctcacag	cagccaagga	acctggggcc	cgctcctccc	ccctccaggc	121
	catgaggatt	ctgcagttaa	tcctgcttgc	tctggcaaca	gggctttag	ggggagagac	181
10	caggatcatc	aagggttcg	agtgaagcc	tcactcccag	ccctggcagg	cagccctggt	241
	cgagaagacg	cggctactct	gtggggcgac	gctcatcgcc	cccagatggc	tcctgacagc	301
	agcccactgc	ctcaagcccc	gctacatagt	tcacctgggg	cagcacaacc	tccagaagga	361
	ggagggctgt	gagcagaccc	ggacagccac	tgagtccttc	ccccaccccg	gcttcaacaa	421
	cagcctcccc	aacaaagacc	accgcaatga	catcatgctg	gtgaagatgg	catcgccagt	481
15	ctccatcacc	tgggctgtgc	gacccctcac	cctctcctca	cgctgtgtca	ctgctggcac	541
	cagctgcctc	atttcgggct	ggggcagcac	gtccagcccc	cagttacgcc	tgccctcacac	601
	cttgcgatgc	gccaacatca	ccatcattga	gcaccagaag	tgtgagaacg	ctacccccgg	661
	caacatcaca	gacaccatgg	tgtgtgccag	cgtgcaggaa	gggggcaagg	actcctgcc	721
	gggtgactcc	gggggccctc	tgggtctgtaa	ccagtctctt	caaggcatta	tctcctgggg	781
20	ccaggatccg	tgtgcgatca	cccgaaagcc	tgggtgtctac	acgaaagtct	gcaaatatgt	841
	ggactggatc	caggagacga	tgaagaacaa	ttagactgga	cccaccacc	acagcccatc	901
	accctccatt	tccacttggg	gtttgggttc	tgttcaactc	gttaataaga	aaccctaagc	961
	caagaccctc	tgcgaacatt	ctttgggcct	cctggactac	aggagatgct	gtcacttaat	1021
	aatcaacctg	gggttcgaaa	tcagtgaagc	ctggattcaa	attctgcctt	gaaatattgt	1081
25	gactctggga	atgacaacac	ctggtttgtt	ctctgttgta	tcccagccc	caaagacagc	1141
	tcctggccat	atatcaaggt	ttcaataaat	atttgctaaa	tgagtg		

SEQ ID NO. 14

KLK11 nucleic acid

30

gene 2313..7622

mRNA join(2313..2398,4189..4263,5061..5217,5545..5810,
6627..6763,7158..7622)

35

CDS join(4224..4263,5061..5217,5545..5810,6627..6763, 7158..7310)

	tgataatagt	gttctctctc	ctcattgggtc	agggccccag	ccattgtcct	tgagagaatg	61
40	ctcgactctt	tatgttgtct	tgacagcctc	ccctgagatt	ggtcattaat	gactgtgctc	121
	tctctcctca	ttggtcaggg	ccccagccat	tgtccttgag	agaacctctg	tcctttatgg	181
	agttccaccc	ttcttccctg	ggattggccc	ctagagacag	tggttcttct	cttttgggtta	241
	gccattgcc	ttgtcctccg	ggaaagtgat	tatactcttt	tgtctaata	ccagacttgg	301
	agccctcccc	aaggcccagg	actgggttga	agggttgggg	aggaaaacag	aaataagatg	361
45	tctcccttgt	tcagacagta	cttctcttcc	cttccagggt	gattctgggg	gccccctggg	421
	gtgtggggga	gtccttcaag	gtctgggtgc	ctgggggtct	gtggggccct	gtggacaaga	481
	tggcatccct	ggagtctaca	cctatatattg	caagtatgtg	gactggatcc	ggatgatcat	541
	gaggaacaac	tgacctgttt	cctccacctc	cacccccacc	ccttaacttg	ggtacccctc	601
	tggccctcag	agcaccaata	tctcctccat	cacttcccct	agctccactc	ttgttggcct	661
50	gggaacttct	tggaaacttta	actcctgcc	gcccttctaa	gacccacgag	cgggggtgaga	721
	gaagtgtgca	atagtctgga	ataaatataa	atgaaggagg	ggccatgtct	gtccatttga	781
	agtcctcatg	ctggttgaga	ctggaagaag	gactcagcag	tttccctatc	tcataaggag	841
	agaaacagag	ctcaaataag	gccaggcaca	gtggctcaca	cctgtaatcc	catcaacttg	901
	ggaagctgag	gcaggtggat	cacctgaggt	caggaactcg	ggaccagcct	ggtcaacata	961
55	gtgaaacccc	aactctacta	aaaatgcaaa	aattagccag	gcatggtggc	gcatgcctgt	1021
	aatcccagct	actcaggagg	ctgagacagg	agaatagcat	gaacccgtga	ggcagagggt	1081
	gcagcgagcc	gagattgaac	cattacactc	cagcctgggc	gacagagcga	gactccatct	1141

	caaaaacaaa	caaacaaaaa	accagtgct	caaataggat	gaggggtcttc	cctgagtagt	1201
	tactcagaaa	tggagtagaa	aaagttactt	ttaataatat	aggccgggtg	cagtggccca	1261
	cgctgtgaat	cccagcactt	tgggaggcog	aggtgggagg	atggcttgag	ctcagatttc	1321
	gagatcagcc	tggcaacaca	gtgaaatctt	gtcactacaa	aaacacaaaa	aattagctgg	1381
5	gtgtggtggt	gcgtgcctgt	agtcccagct	acttgggaag	ctgaggtggg	aggatcaccc	1441
	gagccgggga	ggtggaggct	gcaaagagcc	gagatcatgc	cactgcactc	cagcctgggc	1501
	aataaagtga	gaccttgtct	caaaaacaaa	aaccagcaa	tataaataag	acacatgttt	1561
	cttcatctgg	cataatagaa	atagtgccca	gagcttataa	gcttttcaag	agtcacaaaa	1621
	agaccgaaa	aagaaaaaga	aaattgttag	ctccaaaata	ccagatgaaa	gctgcaaagt	1681
10	caacatttat	gaccatttaa	tccaatgtcc	ataaaacgta	gcattctttc	cactagccaa	1741
	ctgcagttta	ctttcttgta	atgaagcata	cattgtatct	ttaatgtggg	acgtggcttt	1801
	gttctaataa	gacgaagggt	ggagtgcagg	cttggaaagc	aggagagctc	agcctacgtc	1861
	tttaatcctc	ctgcccaccc	cttggattct	gtctccactg	ggactcaaga	ggtgaggaga	1921
	gaccatctcc	ccaaatgcac	tgaagggaaa	ctggaggagg	gagggagtga	ggggtgatca	1981
15	taccagcgga	ggcacatttg	ctgagccccc	ccgcagctctg	ctctttccaa	gtggaccctc	2041
	ctggaagcct	gatcccaacc	tcccctgcaa	gcaggtctgt	cacccccatc	tctcagatga	2101
	agaaactgag	ccttgcaagg	gtggagtccc	ttgtccccac	gtcataaggg	tagtcatagt	2161
	agtaggaaga	ggaagcacct	aggtttgagg	ccagggctgg	ctgctgtcag	aacctaggcc	2221
	ctcccctgcc	ttgtctccaca	cctggtcagg	ggagagaggg	gaggaaagcc	aagggaaggg	2281
20	acctaactga	aaacaaacaa	gctgggagaa	gcaggaatct	gcgctcgggt	tccgcagatg	2341
	cagaggttga	ggtggctgcg	ggactggaaag	tcctcgggca	gaggtctcac	agcagccagt	2401
	aagtgaacag	ctggactcgg	gctgcctggg	cggcagggag	aagcgggcag	gggaaggggc	2461
	agcagaggag	cgaggcccca	gaggagccct	gggggtggagc	acagccaagg	gctctgttcc	2521
	ctttcctgga	ctcggcttcc	acaggccctg	acctgcctcc	cccaccctcc	ggtcctgccc	2581
25	ctgtgcctgg	cagcagcccc	acctgtgtga	catcccagca	cacccccctc	ctccttgcaa	2641
	aggagaaggg	agcggcctag	gggaggccag	gggcccacct	gggctggggc	tgtggagagg	2701
	gagtggctgg	gacgggagga	aaaagagaga	cggagattag	atggaagaag	agggatttca	2761
	agacaaattg	ccagagatgc	agtcagagag	actgactgag	agacacaaag	atagaaggaa	2821
	ttagagaaag	ggccacacag	agccagacag	agagagaaga	gtggagatgg	agacagggac	2881
30	gaggacagag	aaaggcagac	agacacatag	ggacagaaag	agaaaaatca	cacaaagtca	2941
	gaattactga	atgacaggga	atgacacata	gaacgagaca	cagattcaga	gactcagggc	3001
	agggaaagga	aggctgcaga	cagacagaca	gacagaggga	ggctgagaca	cagggagaag	3061
	aggggcttgg	agaggtggca	caggcaggca	gccagtgcct	cagaggcctc	cggggagggc	3121
	cctcacacac	accccgcccc	ggggcattaa	ggcagggctt	ggaggccaat	catcctgggc	3181
35	ccgcccaggg	ccgccccctc	gccagcccgc	ctgcctgggt	cctggcacct	ggcgtcccaa	3241
	cccagcctac	ctgctgtagc	tgcgcctccg	gccgtctccg	ccgccactgg	gccccagag	3301
	ccccagcccc	agagcctgtg	agtcocaggag	gaaagggaag	ctgcccctcc	ccgtccaggt	3361
	gtcagccctc	cccaaggaca	cctgtcccac	tcgggcaccc	atttctccct	ctgctctgtc	3421
	cttctctgct	tgggtggggg	ttcctggcct	ctctctacac	ctctcacctc	cgatggctgt	3481
40	ccgcagcctc	agttacctct	aatctccatg	gcttcagctg	ctgagctggc	cctctgctcc	3541
	cacccccgct	ggccagggca	gcggagggca	ctggccctcc	cctcgaccag	ccccgccag	3601
	ctttgcttgg	ctgtccttca	aaagggcagg	ggtttggcgg	acagggttc	agcaagccgg	3661
	gtgatggggg	tcccagacat	tgtctggggc	tgagccccct	actccccctc	agcagacctc	3721
	aaaggctcca	tatcgctctg	ctgcgaagac	aatgaaaaag	gggtggctac	ggaacgggtg	3781
45	ctggttcccc	ttgtccttcc	accccaagct	gctggggcct	ggccagctct	caaggcaaga	3841
	aggaaaacat	cctctgacat	gtgcggggga	ggtcccatgg	ctgacttgaa	cagggccogaa	3901
	ccatggcttg	acagctcaaa	gccccctcca	acgacttcca	catggttctt	ggtatctcgg	3961
	aagcttctag	ctgtgaccag	gccccctcca	aggccaccct	agacacctaa	gatataatct	4021
	aagtgtttgg	agatctgagt	gctgtgagaa	acaggggatt	tccccaacct	tgtttctccc	4081
50	aagtggggag	cgggagcagg	tgagggagag	aggagagggc	atgagccagc	ccccccctcc	4141
	cgatttcccc	gtaaagtgat	gcggccccc	gtccctcctt	gttcccagag	gaacctgggg	4201
	cccgtcctc	ccccctccag	gccatgagga	ttctgcagtt	aatcctgctt	gctctggcaa	4261
	caggtacgca	ggggatgggg	gcagggcagg	atcctccctc	ttgaatctct	gggatcccc	4321
	aacctctgtg	gtctggacag	tgacagggct	gattccaaat	tacagaacaa	cccataaggc	4381
55	acctgaactg	gagcagtggt	catgagggcc	tggatgccct	tctagataat	ccctttaaat	4441
	gccaaaggag	gagaggtcaa	gggggtcgta	aagggtcccg	tggaggggct	gaggaagctg	4501
	gagttggggg	agcagtcact	caaagcgccc	aggacagggg	ctactgacca	accagtatgg	4561
	aagtatttcc	tttttttttt	ttcccagaga	caaagtcttg	ctctattgtc	caggctggag	4621
	tgccgtggtg	ccaacacggc	tcaactgcagt	cttgacttcc	cgggcttaag	tgatccctaa	4681

	gccatctcag	cttccccggt	agctgggacc	acaggcacct	gccaccaagc	caggctaatt	4741
	gtttaattgt	ttgtagagat	gggggaggag	gtctcactat	gtttgcctag	gctgatctag	4801
	aactcctggg	ctcaagtaat	cctcccacct	tagcctctca	aagtgcctgg	attacaggca	4861
	tgagccactg	catttgacct	tatggaagta	ttttcatcct	ttaataccog	acccagcat	4921
5	ccagggcaac	ccagagggac	accagaccag	ggcccagacc	acccactctc	tttctctctc	4981
	ccccaccccc	atthctggga	gtcctcctgg	tctaccacct	ctccttctctg	agccccctct	5041
	tttgctctca	ccccctccag	ggcttgtagg	gggagagacc	aggatcatca	aggggttcga	5101
	gtgcaagcct	cactcccagc	cctggcaggc	agccctgttc	gagaagacgc	ggctactctg	5161
	tggggcgacg	ctcatcgccc	ccagatggct	cctgacagca	gcccactgcc	tcaagccgtg	5221
10	ggtgccccgg	ctggggcggt	gccgggggtg	ggggctggga	atggggagat	ggatggagag	5281
	aagctcaggg	ataggggtgc	tggtaagggg	attagagatg	gggatgggta	gtgtcagcaa	5341
	ggttgatggg	ctcgagttgg	tattgaaggt	ggggggatga	atgggggttg	gatggggcta	5401
	tggctgggaa	gggggcttcg	gtgggagacg	tggaaagaggt	tggaaagcaga	gcatgttttc	5461
	ttcatcctca	aaggtgtcac	tcacctctcc	cacccatgtc	tcccccgacc	tttctctctc	5521
15	caactactgt	ctctcccacc	tcagccgcta	catagttcac	ctggggcagc	acaacctcca	5581
	gaaggaggag	ggctgtgagc	agaccggagc	agccactgag	tccttccccc	accccggtt	5641
	caacaacagc	ctccccaaaca	aagaccaccg	caatgacatc	atgctgggtga	agatggcatc	5701
	gccagtctcc	atcacctggg	ctgtgcgacc	cctcacccctc	tcctcaogct	gtgtcactgc	5761
20	tggcaccagc	tgccctcattt	ccggctgggg	cagcacgtcc	agccccaggt	gtaggagcac	5821
	cagaggggaa	cctggcaggg	ggtggtgagg	agggagtggg	caggattgtg	gaagggttca	5881
	gggcatcaga	gatgcggttc	acagtgcaga	tgtgggataa	gttgagagga	tgtgtgga	5941
	acgtcaggat	aggggggttg	ggacaaaagt	tggggccttg	gagtcagacg	gacgggat	6001
	gcaatcatac	atccataacc	tcctgggttg	aagaccttag	gcaagcagct	tcacctctct	6061
25	gaatcttgat	tttcttctct	ataaaatgag	aatgattata	cccacctgtc	aggattggat	6121
	tagagataat	gtatatcaag	caactgacat	aaatcattta	ttggatagca	ggctgggac	6181
	cgtggctcac	gcctgtaatc	ccagcacttt	gggaggccga	ggtgggaaga	tcacctgagg	6241
	tcaggacttt	gataccagcc	tggccaacgt	ggtgaaatcc	catctctact	aaaaatgtga	6301
	aaattagttt	ggcgtggttg	tgtgcgcctg	taatcccagc	tactcgggag	gttgaggcag	6361
30	gagaatcgct	taaaacttgg	agacggaggt	tgcagtgcag	caagatcacg	ccactgcact	6421
	ccagcctggg	caacagagca	agactctgtc	tcgaaaaaaa	aaaaaaaaaa	gctgtagtag	6481
	attgctgttg	ctattgttac	aagaagagag	gtgagttggc	tgctgtctaag	gacagggatt	6541
	cccccagggg	cgggatcaca	gcaagcactg	cattagggga	ggtggcaggg	ggctcattcc	6601
	cacagccccct	cacgctgttt	ccacagtacg	cctgcctcac	accttgcat	gcgccaacat	6661
	caccatcatt	gagcaccaga	agtgtgagaa	cgctacccc	ggcaacatca	cagacaccat	6721
35	ggtgtgtgcc	agcgtgcagg	aagggggcaa	ggactcctgc	caggctcagt	tggtctccaa	6781
	ccacagcccc	atccccatcc	ccagcttcaa	tgacatcttt	accgacatcc	acaatttcat	6841
	ccccaacctc	aaccgcgcga	cccctgcaac	tcccaatcca	tctcttcccc	tgttcccggt	6901
	tctgacctca	gcacaaactt	cagctccatc	cccgtttcca	caccatttcc	agctccaacc	6961
40	atccccaaac	tcgtttttga	gctaaccacc	atcctttatc	ccaccataa	tcccagcttt	7021
	atcgctaaac	ctatcacctt	tcccagtgc	taccatcct	gtctcggccc	cactcctaag	7081
	caccgtcccc	acctcctccc	tggctaaccac	cactgtcaac	gctttctctg	accgacattc	7141
	tctctccccg	tgcccagggt	gactccgggg	gccctctggt	ctgtaaccag	tctcttcaag	7201
	gcattatctc	ctggggccag	gatccgtgtg	cgatcaccgc	aaagcctggt	gtctacacga	7261
45	aagtctgcaa	atatgtggac	tggatccagg	agacgatgaa	gaacaattag	actggaccca	7321
	cccaccacag	cccatcacc	tccatttcca	ccttggtgtt	ggttcctggt	cactctgtta	7381
	ataagaaacc	ctaagccaag	accctctacg	aacattcttt	gggcctcctg	gactacagga	7441
	gatgctgtca	cttaataatc	aacctgggg	tcgaaatcag	tgagacctgg	attcaaatcc	7501
	tgccctgaaa	tattgtgact	ctgggaatga	caacacctgg	tttggttctc	gttgatcccc	7561
50	cagccccaaa	gacagctcct	ggccatata	caaggtttca	ataaatattt	gctaaatgag	7621
	tgaatctact	gagtgtttac	tatgtgctag	accctgatcc	aatggctttt	atthttatth	7681
	atthtttgac	agagtctcgc	tctgtcaccc	aggctggagt	acagtgggtc	tatctctgct	7741
	cactgcaacc	tccacctcct	gggttcaagc	aattctcctg	cctcagcctc	ctgaatagct	7801
	gggattacag	gtgcctacca	ccacatccgg	ctaatttttg	tatttttttag	tagagatggg	7861
55	gcttcaccat	gttgccagg	ctgggtctcg	actcctgacc	tcagatgac	tgccctcctt	7921
	ggcctcccaa	actcctggga	ttacagacgt	gagccaccgc	gcccgcggcg	ctttcattta	7981
	ttaattaaaa	gaaattaaat	taattaatct	atthaggaga	cagtcttgct	ctgttgccca	8041
	ggctggagtg	cagtaacaat	cacagctcac	ggcaatctca	atthcctggg	gtcaagtgat	8101
	tgctctccct	cagcctccag	agtagctggg	actacaggca	catgccacga	agcccagcta	8161
	atthttgtat	ttthctgtaga	gacagaggtc	tcagtatggt	gccccggcta	gtctcaaaact	8221

```

      cctgggctca agcagttctgt cctcctcagc ctccaaaagt ggtgagatta caggcatgag 8281
      tcgctgtgcc tggcctccaa gcactttcaa atgtatcaac ttaatcctca caaaaccctg 8341
      tgaggctcggc actgttttca tacctatttt atagttgaag aaacagacac agagaagcaa 8401
      agtcacttgc tcacagtcac gtggctagga gagcaaggat ctgaagcaag gcgatctctt 8461
5      aattaccaag tgatgttcct ggagtaaggc tctgtttggt tcctttcctg taaaatgctg 8521
      catgcaaaaag tataacacag taagtaaaga agtcagttag cctgcacata ctaagacctg 8581
      accaaaggag cttattgttt ttctccaact tccatgatag gtaattagat agtggagacc 8641
      tctgctggcc aatatggtag ccactaaccg cagctggctc ttccaattaa aattacataa 8701
      agccagaaat gtaactcctc tgtctcactt gttatatctc caaggctgga tagccacatg 8761
10      tgactgggtgg tggctggatt agctagtgcg tataaaacat cactgcagaa agttcagctg 8821
      agcagcactg agttagatgg cctctgaaga ggatgtocca cggagagaaat ccagaactca 8881
      ggatctttttt tttttttttt ctttgcgaca gagtcttgct ctgtcaccca ggctggagtg 8941
      cagtggcgtg atctcggctc actgcaactt ctgcctccca ggttcaagca attctcctgc 9001
      ctccagcctcc ctagtagctg ggactacagg cctgtgccaa catccccagc taatttttgt 9061
15      gtcttttttag tagagatggg gtttcactat gttggccagg ctggtctcga actcctgacc

```